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At the moment, one-third of the world’s population is estimated to be infected with 
Mycobacterium tuberculosis (M.tb), the causative agent of tuberculosis (TB) in humans. Our 
treatment strategies have been greatly challenged due to the lack of an effective vaccine and 
the increasing emergence of drug-resistant strains. Following the lead of Gopal Khuller, we 
set out to elucidate a novel drug delivery system based on biodegradable nanoparticles (NPs). 
NPs loaded with anti-mycobacterial drugs, such as rifampicin (RIF), can be used to more 
effectively deliver drugs to the site of infection. In addition, these NPs facilitate sustained 
release and therefore, drastically decrease the number of doses needed during a typical 
treatment regimen. In this thesis, work towards the improvement of TB therapy was executed 
in two separate ways. First, using the Mycobacterium marinum (M.marinum)-zebrafish model 
system established by the group of Lalita Ramakrishnan, we evaluated the effects of the 
antibiotic, RIF, and the anti-mycobacterial compound that blocks bacterial efflux pumps, 
thioridazine (TZ), free in solution. This was accomplished with the use of drug baths; water 
supplemented with the bactericidal agent. With this method the morphological effects could 
readily be observed, and due to the transparency of zebrafish embryos, the fluorescent 
M.marinum bacilli could be visualized in vivo. Second, we were interested in using 
antimicrobial peptides to treat mycobacterial infections, as an alternative to antibiotics. Due to 
the already successful production of NPs loaded with RIF in our group, we sought to 
encapsulate plasmid DNA (pDNA) encoding these antimicrobial peptides using the 
nanoprecipitation method. The effects of different concentrations of RIF and TZ were 
observed in infected and uninfected zebrafish embryos. The infecting bacteria readily 
acquired tolerance towards RIF, as has been shown by others, but higher concentrations were 
found to show higher bactericidal activity and no observable toxicity. TZ is believed to 
increase the effects of antibiotics, such as RIF, and therefore eliminate the transient 
phenomenon of tolerance, but these effects were not observed under the conditions of the 
preliminary experiment performed here. Although pDNA encapsulation was not successful, 
NPs were fabricated in a narrow size range and protocols for preparation of NPs and for the 
analyses of pDNA integrity and loading were established. These protocols provide the 
foundation for others in our group to continue the further development of this promising NP-
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1.1 The burden of tuberculosis  
The infectious agent responsible for the most deaths in the world today is Mycobacterium 
tuberculosis (M.tb), the bacterial pathogen that causes tuberculosis (TB) in humans. In 2010, 
8.8 million people were infected with tuberculosis and 1.4 million died from the disease, 
meaning 3,800 people died every day. In addition, 350,000 HIV positive individuals died 
from TB the same year. [1]  
The most disturbing part may be the fact that at this moment, one-third of the world’s 
population is infected with M.tb but due to latency, only a small proportion of these 
individuals actually become sick. Approximately 10 % of latently infected individuals will 
eventually progress to clinical disease [2]. This is common when the individual is in an 
immune-compromised state, such as old age, malnutrition, or due to HIV co-infection [3].  
Despite these data, the number of TB infections has been declining since 2005, slowly but 
still declining. In 2009, 87 % of patients were successfully treated for TB, the highest rate 
ever [1].  
Although we seem to be moving in the right direction, approximately 440,000 multidrug-
resistant TB (MDR-TB) cases are estimated to emerge every year, and 150,000 people with 
MDR-TB will die as a consequence of it. MDR-TB bacteria are characterized by their 
resistance towards the first-line drugs isoniazid and rifampicin. The bacteria either acquire 
this resistance during treatment of TB or they have already acquired it upon primary infection. 
Unfortunately, in addition to MDR-TB, we also have the emergence of extensively drug-
resistant TB (XDR-TB), which in addition to isoniazid and rifampicin, is also resistant to 
fluoroquinolone and any of the injectable second-line anti-TB drugs [4], such as kanamycin. 
Finally, even totally drug-resistant (TDR) strains have recently been uncovered, which are 
characterized as MDR strains also resistant to all second-line drug classes [5].  
The drugs we have today are effective against TB, but the current treatment regimen requires 
more than 6 months and consists of a cocktail of these drugs. When dealing with drug-
resistant strains, treatment can take more than 2 years and requires the use of less potent 





of patient non-compliance, inadequate health-care oversight, and of course, an increasing 
number of resistant strains [6].  
Therefore, it is safe to say, the need for more effective treatments is immediate and 
compelling. 
1.1.1 Life cycle of Mycobacterium tuberculosis  
M.tbs route of infection is invariably through the inhalation of airborne bacilli and a single 
bacterium may be enough to initiate an infection [6]. 
As depicted in Figure 1:  after M.tb reaches the alveolar space of the human lung the 
bacterium is phagocytosed by alveolar macrophages, which facilitate invasion of the epithelial 
layer in the human lung. Macrophages do not kill the bacterium but, along with dendritic 
cells, carry the bacterium to draining lymph nodes. An inflammatory response is then initiated 
























Figure 1: Infection cycle of M.tb. 
Starting in the alveolar space, this 
figure depicts the sequence of 
events following infection of M.tb. 





The recruited cells will take part in the building of the granuloma (organized aggregates of 
immune cells) and the expansion of the bacterial population. The infected macrophages will 
then differentiate into several specialized cells, including foamy and epithelioid macrophages, 
which will create the core of the granuloma. Eventually, an acquired immune response will 
lead to lymphocytes surrounding the macrophage core in association with a fibrous cuff made 
of extracellular matrix, making up the periphery of the granuloma [6]. 
This phase is typically called the “containment” phase, where the host shows no sign of 
disease, and is not contagious. If a change occurs in the host’s immune status, such as a 
decrease, or increase in pro-inflammatory or anti-inflammatory responses, the center of the 
granuloma undergoes caseation and spills infectious bacilli into the airways. This leads to the 
host coughing and subsequent spread of the bacilli to new hosts [3].  
In humans, the tuberculous granuloma is a highly organized structure that represents a balance 
between host and pathogen. For the host, the granuloma provides a focal point for the immune 
response. It serves to some degree for containment of the infection and, thereby, hopes to 
limit bacterial dissemination. For the pathogen, the pro-inflammatory environment of the 
granuloma recruits potential host cells and maintains lymphocytes at the periphery of the 
structure, where macrophage activation is likely to be less effective [7]. 
1.1.2 How does Mycobacterium tuberculosis survive inside 
macrophages? 
Many different kinds of macrophages are able to phagocytose M.tb. One major route of 
uptake for mycobacteria upon contact with macrophages is through complement receptors and 
complement opsonization, (the binding of complement factors to the bacteria) [8]. In addition, 
other receptors have been implicated, including mannose receptors, Toll-like receptors 2 and 
4, surfactant protein A receptors, CD14, and scavenger receptors [9].  
After uptake into macrophages, the mycobacteria-containing phagosome does not follow the 
normal phagosomal maturation pathway. Sequential fusion with early and late endosomes, 
and finally lysosomes, creates an increasingly more acidic and acid hydrolase-rich 
environment, eventually leading to the destruction of the bacteria. Rather, phagosome 
maturation is arrested in an early maturation state, where the phagosome fails to fuse with 
lysosomes. 





stages marked by the regulatory GTPase Rab5 (an early endosome marker) and Rab7 (a late 
endosome and lysosome marker). They showed that Rab7 never associates with the 
mycobacterium-containing compartment, indicating the failure to fuse with lysosomes and, 





It is believed that the pathogen blocks Ca
2+
 fluxes, which through subsequent steps, leads to a 
block in the fusion with lysosomes [8]. This allows the pathogen to reside inside a 
phagosomal compartment, with a pH of 6.0 - 6.4, avoiding the more acidic and hostile 
environment of the lysosome, with a pH < 5 [11]. 
The compartment containing the mycobacterium may be arrested in development but it is by 
no means static. They are still accessible to fusion with recycling endosomes, giving the 
pathogen access to nutrients such as iron, provided by transferrin and the transferrin receptor 
[11]. This access to iron is crucial for the success of the pathogen.   
Late endosome/lysosome 














Figure 2: Phagosomal maturation pathway with pathogenic (left) and non-pathogenic (right) 
mycobacteria. Pathogenic mycobacteria have the ability to inhibit the fusion of late endosomes and lysosomes 
to the phagosomal compartment in which they reside, and therefore escape degradation by acid hydrolases, 
such as cathepsins. Rab5 and EEA1 (early endosome antigen 1) mark the early endosomal compartments. 
Rab7, LAMP1 (lysosomal-associated membrane protein 1), cathepsins and V-ATPases mark the late 





In a controversial study performed by van der Wel et al. 2007, evidence was provided for the 
phagolysosomal escape of M.tb into the cytosol of cultured dendritic cells and macrophages 
after 48 h of infection [12]. This issue caused some debate, due to the difficulties in 
interpretation of the results, but recently new results reported by Simeone et al. 2012 support 
these findings, at least under conditions that lead to necrosis. They show that virulent 
mycobacteria infecting human macrophages escape the phagosome at a later time during 
infection and that this escape is induced by virulence factors produced by the bacteria. Mutant 
bacteria lacking these virulence factors do not escape the phagosomal compartment. In 
addition, they discovered that this feature was a prelude to the death of the host cell, possibly 
allowing the bacteria to proliferate in the extracellular core of the granuloma, in vivo. [13] 
However, the question of whether or not host cell death is beneficial for the pathogen is still 
undecided. It should also be noted that there are studies that do not agree with this 
interpretation. Jordao et al. 2008 showed that M.tb and the related pathogen Mycobacterium 
bovis are restricted to phagosomes in different types of macrophages for several days of 
infection [14]. 
The contradictions in results concerning tuberculosis just go to show that due to our lack of 
knowledge on this topic, a complete understanding of the intracellular behavior of this 
bacterium has not yet been acquired.   
1.2 Antimicrobial agents 
Due to the problems associated with M.tb infection noted above, such as the increasing cases 
of drug-resistant strains, new therapeutic strategies or agents for TB need to be uncovered. 
We can either strive to improve existing systems, such as the treatment regimen offered today, 
or we can look to something entirely new, such as anti-microbial peptides.   
1.2.1 Antimicrobial peptides as novel anti-mycobacterial agents 
Our airways are covered with a mucin-rich fluid where we can find antimicrobial peptides and 
proteins. These, in association with the innate immune system, will work together to eliminate 
foreign objects, such as bacteria, from the airways and alveoli. [15] Based on this, and our 
general knowledge of antimicrobial peptides, one can conclude that these peptides have the 





peptides include: an individual peptide shows activity towards many different 
microorganisms, including drug-resistant strains; a different mechanism is applied in their 
microbicidal activity; and the development of complete resistance is thought to be very 
unlikely, as it takes a large number of passages in suboptimal concentrations to achieve low 
levels of resistance. [16] 
Collectively, their most important feature is their cationic nature, brought about by their high 
abundance of positively charged amino acids. This allows the peptides to associate with the 
negatively charged surface of bacteria and facilitate permeabilization of their membranes [17-
19].  
Found in humans and other mammals, there are two main antimicrobial peptide families: 
defensins and cathelicidins [17]. In addition, I will refer to two other antimicrobial peptides: 
NK-lysin and Ciona-molecule against microbes (Ci-MAM-A24), and discuss their potential 
as novel peptide antibiotics, which have been and are still being extensively researched.  
Defensins 
Defensins are a family of antimicrobial peptides that are primarily divided into two 
subfamilies: α- and β-defensins [15, 17]. Defensins are found in cells and tissues that are a 
part of the host’s defense against pathogens and in many animals they are most often found in 
granules of either leukocytes [20] or Paneth cells of the intestine. After permeabilization of a 
bacterial membrane, the biosynthesis of most macromolecules (DNA, RNA, proteins and 
lipids) is inhibited, no doubt adding to the lethal effects of these peptides [17, 21].  
In addition to their killing capacities, some defensins have been reported to have chemotactic 
abilities towards various immune cells (monocytes, dendritic cells and T cells) [17, 22].    
α-Defensins are mainly produced by neutrophils and there are six of them: human neutrophil 
peptides (HNPs) 1-4 are found in the azurophilic granules of neutrophils [20], while α-
defensins 5 and 6 can be found, as mentioned above, in Paneth cells in the intestine [23].  
α-Defensins have been found at significant concentrations in the plasma and bronchoalveolar 
lavage fluid of patients with TB, indicating that they play a crucial role in the host’s defense 
against M.tb [24]. This and their known microbicidal effects lead to the natural thought of 
using them as anti-mycobacterial agents. 
Indeed, HNP-1, -2 and -3 have been shown to have microbicidal activity against a wide range 





concentration of 50 µg/ml was reported to kill M.tb by Miyakawa et al. in 1996 [26]. One of 
the follow-up experiments done by Sharma et al. showed that culturing M.tb-infected 
macrophages in the presence of 5 mg/ml HNP-1 was sufficient to kill ~47 % of intracellular 
bacteria after 3 days of treatment [27]. Later, the same group made an even more convincing 
case for the potential of HNP-1 as an anti-mycobacterial agent by using it to treat mice 
infected with TB. After treatment, a significant decrease of CFU (colony forming unit) was 
accomplished in mice. [28]     
β-Defensins are mostly expressed in various epithelial tissues [17] and all human β-defensins 
(HBD 1-4) are expressed in the airway epithelia [15]. HBD-1 alone has been shown to have 
anti-mycobacterial activity against M.tb in vitro, and even more so in combination with the 
antibiotic isoniazid [29]. Even so, the most promising work has been done with HBD-2. 
Human alveolar macrophages do not express defensins naturally, not even upon challenge 
with M.tb; these peptides are expressed by lung epithelial cells [30]. Since these macrophages 
are most likely the first cells a mycobacterium encounters, one might expect that this is the 
location were the highest concentration of antimicrobial peptides should be. Therefore, Kisich 
et al. 2001 took matters into their own hands and used mRNA encoding HBD-2 to transfect 
into and treat M.tb-infected macrophages. They reported a high transfection-efficiency and 
subsequently also enhanced microbicidal activity leading to inhibition of bacterial growth 
compared to controls. [31]    
Even though different methods are used in these examples, the combined message is clear: 
defensins have the potential to be used as effective peptide antibiotics against M.tb. 
Cathelicidin    
Cathelicidins are a family of antimicrobial peptides that take part in the innate immunity of 
mammals. The peptides are characterized by their conserved N-terminal domain, called the 
cathelin domain, but they also contain a heterogeneous C-terminal domain which, after 
proteolytic cleavage, will induce the peptide’s antimicrobial activity. We only know of one 
human cathelicidin, LL-37, which is the C-terminal domain of human cationic antimicrobial 
protein 18 (hCAP18) [32]. Cathelicidin is found throughout the body in different cell types 
ranging from epithelial cells [33] to different leukocytes (natural killer (NK) cells, 
macrophages, T cells etc.) [19]. It has broad-spectrum microbicidal activities; it kills both 





important during M.tb infection. Rivas-Santiago et al. 2008 [35] reported the presence of 
cathelicidin in M.tb-infected lung epithelial cells, neutrophils, monocyte-derived macrophages 
and alveolar macrophages, in which alveolar macrophages presented the highest levels of 
expression. In addition, cathelicidin was shown, by electron microscopy, to associate directly 
with phagocytosed M.tb but the peptide was not detected in granulomas, indicating its 
primary role is during early infection. More directly, Liu et al. 2006 have shown that up-
regulation of cathelicidin leads to increased intracellular killing of M.tb [36]. 
Cathelicidin has also been shown to have chemotactic abilities, specifically towards 
polymorphonuclear leukocytes and CD4
+
 T cells. This indicates that cathelicidin, like 
defensins, can function as a bridge between innate and adaptive immunity, and more 
generally that antimicrobial peptides can have a dual function in TB infection: as a peptide 
antibiotic and as a signaling molecule that helps to attract key immune cells to the sites of 
infection. 
NK-lysin 
NK-lysin is an antimicrobial peptide isolated from pig NK cells and cytotoxic T cells, and is 
homologous to human granulysin [37, 38]. It is stored in granules produced by these cells and 
has shown microbicidal activity towards a range of pathogens [37], including mycobacteria 
[18, 38]. NK-2, a shortened version of NK-lysin, was shown to kill 70 – 80 % of 
mycobacteria in culture and decrease the bacterial load in infected macrophages, without any 
cytotoxic effects [18]. Specifically, both synthetic versions and native NK-lysin have been 
shown to inhibit M.tb growth; 90 % inhibition for the synthetic peptides and 60 % inhibition 
for the native peptide [38].  
Ci-MAM-A24    
A novel family of antimicrobial peptides was reported by Fedders et al. in 2008 after they had 
identified them in the sea squirt Ciona intestinalis using bioinformatics tools, and with this 
information they made a synthetic peptide corresponding to its cationic core, namely Ci-
MAM-A24. The native peptide was localized to specific granule containing haemocytes and 
its synthetic counterpart was shown to have microbicidal activity towards a wide range of 
microorganisms. In addition, it was found to be very salt-tolerant making it suitable for 





found to kill 45 – 78 % of bacteria in vitro at micromolar concentrations. In cell culture, 
mycobacterial killing was non-significant and Ci-MAM-A24 appeared to have partial 
cytotoxic effects on macrophages, in contrast to what had been reported before for 
erythrocytes. Interestingly, Ci-MAM-A24 in combination with NK-2 facilitated the best 
killing, both extra- and intracellularly, and together showed no cytotoxicity towards 
macrophages. [18]  
Later it was discovered that Ci-MAM-24 had very potent microbicidal activity towards drug-
resistant strains as well, such as methicillin-resistant Staphylococcus aureus (MRSA) [40], 
underscoring the promising potential these peptide antibiotics have as novel therapeutics.    
1.2.2 Antibiotics and other anti-mycobacterial agents 
Antibiotics – Rifampicin 
For treatment of TB we have four first-line antibiotics: isoniazid, rifampicin, pyrazinamide 
and ethambutol. A treatment regimen usually consists of a combination of these drugs: 
isoniazid and rifampicin or isoniazid, rifampicin and pyrazinamide. [41] This multi-agent 
therapy for TB was proposed after streptomycin resistance was observed already in the early 
clinical trials, shortly after that drug had been introduced [42]. 
Rifampicin (RIF), discovered in 1965, is a descendent of rifamycin, an agent isolated in 1957 
from the bacterial species Amycolatopsis rifamycinica. In addition to RIF, there are several 
antimicrobial agents in the rifamycin family today, all developed through subsequent 
chemical modifications. [43] RIF has a significant effect on metabolically active M.tb and 
shows late sterilizing action towards semi-dormant organisms, that are induced to undergo 
sudden bursts of metabolic activity. This late effect of RIF has allowed treatment of TB to be 
reduced from 1 year to 6 months, highlighting the important role RIF plays in TB therapy. 
RIF’s antibacterial activity is attributed by its ability to bind and inhibit DNA-dependent 
RNA-polymerase, thereby inhibiting transcription, and as a consequence protein expression. 
Resistance to RIF occurs via mutations within the gene that encodes the β-subunit of the RNA 
polymerase. However, resistance to RIF by itself is rare. Usually, resistance towards RIF only 
occurs in strains that are already resistant to isoniazid, which is how multi-drug resistance is 
defined in TB patients. [44] The clinical concentration of RIF is very high; 600 mg/day [45]. 





are associated with the combined use of RIF and isoniazid; but in general, RIF is a well-
tolerated drug [46].    
Phenothiazines – Thioridazine  
Phenothiazines are a group of related compounds that possess many different characteristics; 
one being anti-tubercular activity. Traditionally, phenothiazines have been used as anti-
psychotic agents but their anti-tubercular activity has also been known for quite some time. 
Due to the discovery of potent antibiotics such as rifampicin, and the adverse side effects 
associated with these compounds, the phenothiazines were set aside. Now that drug-resistance 
has become a problem, their potential has again been recognized. [5] 
 
The most potent phenothiazines are thioridazine (TZ) and chlorpromazine, but due to the high 
level of toxicity associated with chlorpromazine, TZ is usually chosen for use in infection-
studies [47]. TZ is thought to have several microbicidal activities: increase in macrophage 
killing efficiency; reversal of drug resistance; inhibition of gene expression of efflux pumps, 
but most importantly, it also inhibits bacterial efflux pumps directly. Drug-resistant bacteria 
are known to have efflux pumps that extrude antibiotics before they get a chance to affect the 
bacterium in any way. Inhibition of these pumps by TZ makes resistant bacteria susceptible to 
the drug again. [48]  
Initially, it was deemed a problem that in vitro concentrations (15 – 30 µg/ml, depending on 
drug-susceptibility) [49] were far exceeding the limit of what could be used in vivo (0.5-1 
µg/ml, used in long-term anti-psychotic treatment) [5], but because macrophages concentrate 
phenothiazines up to 100-fold, one can safely use a low concentration and at the same time 
achieve intracellular mycobactericidal activity [50, 51]. Indeed, 0.1 µg/ml of TZ was shown 
to kill both antibiotic-susceptible and MDR strains of M.tb within 1 day post infection in 
macrophages [49]. This 100-fold concentration by macrophages could be the result of TZ 
affecting macrophage efflux pumps as it does bacterial efflux pumps. 
 In vivo results with TZ show significant killing of the bacteria in mice infected with drug-
susceptible M.tb, even more so in combination with first-line antibiotics. TZ activity was also 
shown to induce significant killing when infection was caused by an MDR-TB strain. [52]     
Many questions concerning TZ still need to be answered but the data show that it can be used 





can help bring these antibiotics back to their Golden-era; when their activities changed TB 
therapy to the better.  
1.3 Zebrafish and Mycobacterium marinum as 
model systems to study tuberculosis  
1.3.1 The zebrafish (Danio rerio) 
The zebrafish was first identified in the river Ganges in India by Francis Hamilton in 1822 
[53], but the man who opened the scientific world’s eyes to the zebrafish, Danio rerio, as a 
model organism, was George Streisinger, who began working with the fish in the late 1960s. 
He used the zebrafish to study embryonic development through mutational analysis [54] but 
before him this fish had already been used to study embryogenesis for more than 100 years 
[55]. Some of the reasons for why this is such a good model are: the fact that the organism has 
a short generation time; a single female can produce up to 200 embryos per mating; they are 
of small size and can be kept at high population density (5 fish/liter); mutagenesis is easily 
performed; embryos develop externally; and due to their transparency at the embryo- and 
early larval stage, many processes can readily be visualized through light microscopy. [54, 
56] Also, transparent mutants exist that retain their transparency throughout life [57]. 
In addition, many genetic analyses can be performed on the zebrafish: both forward and 
reverse genetic analyses; microarrays and mutants are commercially available; and gene-
specific, transient knockdown can be performed using morpholino oligonucleotides. 
Morpholinos are antisense oligonucleotides that block RNA translation, either by binding to 
the translational start site or intron-exon junctions to create non-functional splice variants 
[58].  
Zebrafish embryos have also proven to be useful for chemical screens, because of their small 
size and the fact that they can absorb chemicals that are present in their aqueous environment 
through their skin. The compound of interest can, therefore, easily be administered to the 
water and the effects can readily be observed [56, 59]. This again gives us the advantage of 
studying the effects of novel anti-microbial agents in vivo. 
When it comes to immunological studies the zebrafish has one big advantage. As an adult the 





only the innate immune system is functional. T cell progenitors migrate to the thymus at 3 
days post fertilization (dpf) but the adaptive immune system does not become functional until 
4 – 6 weeks post fertilization [60]. This makes it possible to study the factors of innate 
immunity without interference from the adaptive immune system. In a paper published by the 
Ramakrishnan group, they use this to their advantage when they disprove the preconceived 
notion that adaptive immunity is crucial for granuloma formation in tuberculosis, with the use 
of zebrafish embryos and Mycobacterium marinum (M.marinum) [61].  
1.3.2 Mycobacterium marinum   
Like M.tb, M.marinum is a rod-shaped bacterium, with unique lipids called, mycolic acids, 
present on its surface. This makes the surface waxy and hydrophobic, and prevents the use of 
the traditional Gram stain. Instead an acid-fast Ziehl-Neelsen stain needs to be used [62]. It is 
an aerobic bacterium that grows optimally in the dark. When grown in the light, pigments are 
produced, consistent with it being defined as a photochromogen [63]. This bacterium is an 
aquatic organism, naturally infecting fish and amphibians. Therefore, its optimal growth 
temperature naturally lies between 25° and 35°C. M.marinum has a generation time of 6 – 8 
hours [63], making it a fast grower compared to M.tb, which has a generation time of more 
than 20 hours. Because it does not grow well in the human body at a temperature of 37°C, if 
infected, one tends to find infectious lesions in the cooler, superficial regions of the human 
body, which are referred to as swimming pool granulomas. M.marinum very rarely causes a 
systemic infection. [64]  
Tønjum et al. 1998 suggested that M.marinum could be used as a model organism for M.tb. 
They performed gas chromatography of fatty acids and alcohols, DNA-DNA hybridization, 
and 16S rRNA gene sequence analyses to clarify the relationship between four different 
mycobacterial species; M.marinum being one of them. What they found was two 
mycobacteria, M.marinum and Mycobacterium ulcerans, that were more closely related to 
M.tb than any other mycobacterial species (Figure 3) [65]. 
In addition to being close relatives, M.marinum and M.tb appear to “behave” the same way. 
They are both phagocytosed by macrophages, inhibit the maturation of the phagosome into a 
phagolysosome, and they produce granulomas with the same characteristics in their natural 





Through the pioneering work of Lalita Ramakrishnan and her group, it has unequivocally 
been demonstrated that M.marinum is a good model for studying M.tb in humans. [56, 67, 68] 
 
Figure 3: Phylogenetic tree showing the genetic relationships between mycobacterial species. The figure is 
taken from Tønjum et al. 1998 [65]. 
1.3.3 The zebrafish as a model for studying infectious disease 
The relationship between host and pathogen is a complex one. So when developing novel 
drugs against infectious diseases, or in our case a drug delivery system, an animal model is 
needed. Drugs that show promise in vitro may not have the same effect in vivo [56]. 
It has been shown in several reviews that the human and zebrafish immune systems are 
surprisingly alike, for example homologues of all 10 human Toll-like receptor (TLR) families 
have been identified in zebrafish [69-71]. In addition, expression of NK-lysin in zebrafish has 
been proven [72] and 3 β-defensin like genes have been identified [73], meaning, as in 
humans, antimicrobial peptides are important components of the innate immune system.  
The advantages listed earlier (transparency, in vivo imaging, mutagenesis, etc.) are 








The M.marinum-zebrafish model for human tuberculosis 
There are several model organisms used for the study of tuberculosis and even though humans 
are its natural host, all of them are susceptible to M.tb infection. The mouse has mostly been 
used for these studies. This is due to the vast amount of knowledge and molecular tools, such 
as antibodies, we already have for this organism, but there are also some disadvantages: latent 
infection is hard to obtain and the granulomas that form are quite different from human 
granulomas. Usually human granulomas are well-defined and organized structures that often 
develop a caseating necrotic core. In mice the granulomas that form during infection are the 
opposite: they are not organized and they do not develop a caseating necrotic core. 
Other models include guinea pigs, rabbits, and non-human primates, all with their own 
advantages and disadvantages. Guinea pigs for example form human-like granulomas but are 
extremely sensitive to the disease and die rapidly [74]. 
In addition, we now also have non-mammalian model organisms, namely the leopard frog 
(Rana pipiens) and the zebrafish, which can be infected with M.marinum. The leopard frog 
has been shown to develop non-caseating and tightly organized granulomas and the infection 
produced is long-term with no symptoms, making this a good model for latent TB infection 
[75, 76]. When it comes to adult zebrafish, infection with M.marinum causes the production 
of organized and caseating granulomas, which are very similar to human granulomas, an 
important factor that shows how suitable the M.marinum-zebrafish model is to study active 
tuberculosis [66, 75]. This has also been shown to be the case upon infection of embryos [61].  
Also, the M.marinum and M.tb infections themselves have proven to have many similarities. 
In addition to zebrafish-specific TLRs, infection with M.marinum has been shown to induce 
expression of TLRs that are homologues of human TLRs expressed during human TB 
infection [71]. 
The zebrafish embryo model makes in vivo imaging of interactions between the host and the 
pathogen possible, and mutational analysis of both host and pathogen can be performed, as 
done in the Ramakrishnan group. One of the first major observations made in this system 
helps to rationalize how M.tb can survive essentially for dozens of years as an intracellular 
pathogen, when macrophages normally have a life-span of a couple of weeks [77]. Davis et al. 
2002 saw that uninfected macrophages can be induced to migrate towards the infected 





of specific virulence factors, which will be discussed in more detail below [61, 78]. They also 
witnessed, for the first time, an uninfected macrophage phagocytosing another macrophage 
infected with M.marinum, which has been shown to be a means of bacterial dissemination; 
allowing passage of the infection from one macrophage to another without interference from 
the immune system [61].   
Further innovative use of this system went into comparing the pathogenesis of wild-type 
(WT) M.marinum to a mutant they call ΔRD1. This mutant is lacking the RD1 (region of 
difference 1) locus, the same locus that is missing in attenuated bacille Calmette-Guérin 
(BCG) vaccine strains [78]. The locus encodes a secretion system for mycobacterial virulence 
factors, also encoded within the same locus, that are injected via the secretion system into the 
host cell. Of these factors, the best characterized are ESAT-6 (6 kDa early secretory antigenic 
target) and CFP-10 (10 kDa culture filtrate protein), which are vital for the virulence of 
mycobacteria; namely, granuloma formation and bacterial dissemination therein [78, 79]. 
With these results, and those from Cosma et al. 2004, where superinfecting M.marinum were 
shown to penetrate pre-existing granulomas and thrive there [80], the traditional view of the 
granuloma as a purely host-protective structure was greatly challenged.  
In another powerful example of the strength of this model system, the same group used a 
morpholino to knock out the myeloid transcription factor gene pu.1, which is needed for the 
differentiation of macrophages; thereby creating embryos without macrophages. With this 
approach, they discovered that when the pu.1 mutant zebrafish were infected with WT 
M.marinum, the bacterial burden was 10-fold higher than in the control fish with 
macrophages at 4 days post infection (dpi), suggesting that early on, macrophages play a 
crucial role in controlling the infection. This result was in support of the granuloma being a 
host-protective structure, where macrophages greatly reduce bacterial growth.  
On the other hand, upon further inspection they also established that the mycobacteria are 
fully dependent on macrophages to cross the epithelial barriers. [81] Taken together these 
results show the “give and take” relationship that has evolved over time between host and 
pathogen and the dual role the macrophage plays during infection; limiting bacterial numbers 
and enabling the bacteria to disseminate into deeper tissues where they can establish an 
infection [81].  
These are just some examples of the high quality of work that has come from the 





in 2012 [82], where their collective results shine a new light on the traditional view of the 
granuloma. The granuloma no longer “walls off” the infection and creates a barrier in which 
almost no bacterial proliferation occurs. It is a dynamic, and also a pathogen-favorable 
structure. Mycobacteria are able to exploit granuloma formation for their proliferation and 
dissemination, both within the granuloma and to other sites in the body where a new 
granuloma can be initiated. Instead of blocking immune responses the bacteria seem to 
accelerate them to use to their advantage, such as the constant recruitment of macrophages to 
the granuloma, which facilitates bacterial dissemination [82, 83].   
Overall, the large body of work carried out by the Ramakrishnan group, as well as others, 
make a compelling case that the M.marinum- zebrafish model is a powerful system that gives 
important insights that are relevant for understanding the pathogenesis of M.tb [56, 67, 68]. 
All these reasons are in support of our choice to make use of this model system. 
1.4 Nanoparticles in therapy of infectious disease 
1.4.1 Background 
Antibiotics are traditionally administrated orally in the form of tablets and the oral absorption 
of, for example RIF, is controversial. During the first hours after administration, plasma levels 
peak and eventually the drug is broken down by the liver or excreted through the kidneys. 
[45] This systemic release may lead to toxic side-effects [46] and depending on the 
physicochemical properties of the drug, may not reach its target site in a therapeutic 
concentration [84]. The advent of nanotechnology has provided a more attractive concept for 
drug delivery, in the form of biodegradable polymer nanoparticles (NPs) that can be 
formulated such that the drug is enclosed (and protected) in the NP. As the NP-containing 
endo-/phago-somal compartment matures the pH will decrease and degradation of the NPs 
will lead to subsequent drug release [85].  
In our case the encapsulation of drug means the drug is entrapped in the polymer matrix of the 
particle, which is then called a nanosphere. Throughout this thesis this type of particle will 






After learning of the work of Gopal Khuller and his group (which will be decribed in more 
detail later), where encapsulated anti-tubercular drugs were being used in animal models to 
treat tuberculosis, we decided to combine his work and the work of Lalita Ramakrishnan 
(mentioned earlier), to work towards a better understanding of TB pathogenesis and more 
importantly, treatment.  
1.4.2 Nanoparticle formulation 
NPs are defined as being less than 1 µm in diameter and are made of natural or synthetic 
polymers [86]. Some examples include poly (lactic-co-glycolic acid) (PLGA), poly-lactic 
acid, chitosan, alginate, and lipids, to name a few [87]. The most widely used is PLGA, a 
polymer that has long been approved for use in humans by the US Food and Drug 
Administration. It is biocompatible and biodegradable, two crucial characteristics for NPs in 
drug therapy [85].  
NPs can be used for the encapsulation of many different agents: hydrophobic drugs, 
hydrophilic drugs, proteins and peptides, vaccines, and biological macromolecules, such as 
plasmid DNA (pDNA) [86]. Our group’s starting point was the encapsulation of the 
hydrophobic antibiotic RIF, this being based on the success of Gopal Khuller and others in 
this area, which will be mentioned later. 
There are several preparation methods for NPs. Which method one chooses depends mainly 
on what needs to be encapsulated. For hydophobic compounds, such as RIF, the most 
common NP preparation technique can be used: the emulsion-solvent evaporation technique, 
also called a single emulsion or oil-in-water (o/w) emulsion. For hydrophilic compounds, 
such as DNA, and proteins you can use a modification of this technique, a so-called double 
Figure 4: Illustration of a nanosphere. The drug 





emulsion or water-in-oil-in-water (w/o/w) emulsion [86]. Another method that can be used for 
encapsulation of both hydrophilic and hydrophobic compounds, is nanoprecipitation, where 
no emulsion is prepared because the particles form spontaneously [88, 89]. This method will 
be explained later in more detail for the encapsulation of pDNA.  
Modifications to the NPs can be made. We know that specific cell surface receptors can either 
be over-expressed or expressed exclusively in specific tissues, and this can be used to our 
advantage by binding the corresponding ligand to the surface of NPs. With this and 
monoclonal antibodies available one can facilitate targeted and sustained treatment. [84, 90] 
One example of such is mannose. Mannose receptors are found on the cell surfaces of 
macrophages and dendritic cells and the presence of mannose on the surface of NPs may 
promote a higher uptake by macrophages, compared to unmodified NPs [91].  In another 
example, coating of NPs with the lectin, wheat germ agglutinin (which binds sialic acid and 
N-acetylglucosamine), will facilitate the binding of NPs to intestinal and alveolar epithelium, 
making them suitable for both oral and aerosol delivery. Because of this “entrapment” at a 
specific site in the body, the presence of drug in plasma has been shown to be prolonged in 
comparison to NPs without lectins, making it possible to decrease the dosage number [92].  
1.4.3 Nanoparticles and tuberculosis 
As in the case of TB and other intracellular pathogens, treatment usually involves long-term 
therapy with a combination of drugs. Due to the length of therapy, and the often frequent 
administration of drugs, side-effects due to toxicity commonly arise, leading to patient non-
compliance that again can lead to the development of drug-resistant bacteria. In addition, the 
cost of this treatment regimen is high. [6, 87]  
In general, to treat intracellular pathogens, a sufficient amount of active drug needs to reach 
the compartment in which the pathogen is hiding, whether it be the phagosome (as in the case 
of TB), a vacuole (Salmonella) or the cytosol (Listeria) [8, 93, 94]. To get to these 
compartments a drug needs to cross the cell membrane, reach the pathogen, and do so in a 
high enough concentration as to reach therapeutic levels, which may be a problem depending 
on the molecule’s physicochemical properties [84, 87]. In addition, many drugs are 
unfortunately very toxic, not only do they kill the pathogen, they also damage healthy tissue 





Upon administration, whether it is through injection, oral, or aerosol, the NPs are identified by 
the immune system as foreign objects. Phagocytic cells, such as macrophages, will naturally 
engulf the NPs. In terms of using NPs as therapy against TB, this is very advantageous. As 
described above, M.tb is an intracellular pathogen of macrophages, the same cells that later 
will make up most of the granuloma. In this case, designing a targeting system is not essential 
as the NPs are naturally targeted to the infected cells and eventually the site of infection itself, 
the granuloma, where they can facilitate targeted and sustained release of the drug. [9, 84, 87] 
Actually, upon uptake of microparticles containing antibiotics, the intracellular drug 
concentration in macrophages compared to the extracellular concentration when free drug is 
used, has been shown to be up to 10 times more [95]. This indicates how advantageous NP-
based drug delivery can be in treatment of intracellular pathogens.  
As mentioned, TB therapy is tedious and costly and often leads to non-compliance in patients. 
Creating a drug delivery system that can overcome these obstacles and provide a sustained 
and site-specific drug release would be most advantageous. With this we can avoid the 
toxicity issues when taking drugs for a long period of time by lowering the dosage amount 
and the frequency of drug administration [87, 96]. 
Through the work of Gopal Khuller and his group we have learned just how effective 
treatment with NPs can be. They have shown that by both oral [97, 98] and aerosol [99] 
administration of anti-tubercular drug-loaded NPs, sustained drug delivery is accomplished. 
The oral administration of free RIF versus encapsulated RIF is depicted in Figure 5. Here we 
can see that free RIF peaks early and clears the body in 24 h. The RIF-NPs on the other hand 
facilitate a so-called “burst release”, thought to be facilitated by drug in association with the 
NP surface [86], and then sustained release is established in plasma for 6 days. In the tissues 
however, therapeutic levels of drugs could be detected for 10-11 days. This allowed M.tb-
infected animals to receive therapy every 10 days instead of the traditional daily dose of free 
drug during a 46 day monitoring period. Meaning, 5 doses of RIF-NPs can replace 46 daily 
doses of free drug and still clear the infection [97, 99]. In addition this therapy was further 
improved by coating the PLGA NPs with a lectin. As explained above, the drug remained at 
therapeutic concentrations in the plasma for a longer period of time as compared to drug 
released from unmodified NPs, making it possible to decrease the number of NP doses from 






The advantages are clear: (1) frequency of dosage is greatly reduced so non-compliance 
should not be as big a problem (it is also foreseen that this property would be an advantage in 
treating drug-resistant strains); (2) the local concentration of drugs (intracellular) is higher 
than the systemic concentration, leading to reduced toxicity [95]; (3) targeted and sustained 
release of the drug is accomplished at therapeutic concentrations; and (4) the amount of drug 
needed for therapy can be reduced, making the therapy less costly. This was shown by 
Sharma et al. 2004 with the use of NPs loaded with two-thirds of the therapeutic dose to clear 
an M.tb-infection in guinea pigs. This was done over the same time-period as mentioned 
above (46 days) with the same number of doses (5 doses) [98].  
1.4.4 Nanoparticles and DNA 
Another promising field of NP-based delivery systems is DNA delivery, whether it is as 
vaccines or gene therapy the advantages are many. We were interested in this approach 
because of the attractive possibility of encapsulating pDNA encoding anti-microbial peptides, 
e.g. LL-37, that have been shown to be effective against M.tb and other mycobacteria both in 
vitro and in vivo.  
In the case of oral administration of drugs, there are critical obstacles to overcome: the hostile 
environment of the stomach and crossing the epithelial layer in the intestine to reach 
circulation. In addition to the obstacles mentioned earlier, for DNA delivery there are 
additional obstacles: the need to cross the endosomal membrane and after entering the 
cytoplasm, to enter the nucleus [100]. NPs can help to overcome these obstacles.  
Figure 5: RIF concentration after one oral 
administration of either free or encapsulated drug to 





An ideal DNA delivery system should fulfill some requirements: (1) the particles should 
contain a high amount of intact DNA; (2) the polymer should protect the DNA against 
nuclease degradation; and (3) the burst release should be as low as possible to avoid loss of 
DNA. [101] 
These requirements have proven difficult to achieve but advances have been made.  
DNA carrier systems made of PLGA are mostly produced using the double emulsion-solvent 
evaporation technique, but there are usually some problems associated with this procedure. 
During production, DNA comes into contact with organic solvents and is subjected to the 
shearing effects of sonication or homogenization, possibly leading to the destruction of the 
molecule. [102, 103] Many solutions have been provided to circumvent these problems, the 
most drastic being the use of a different polymer, such as chitosan, a natural polymer that is 
considered non-toxic and biodegradable, has mucoadhesive properties and can increase 
cellular permeability [100].  
Opinions, and results, differ on how much damage DNA suffers under the conditions of 
particle preparation. Some show that the polymer itself protects DNA from both shearing and 
nuclease activity [104, 105], while others propose the use of protective buffers during the 
process [106]. Others again suggest the use cationic polymers, such as polyethyleneimine 
(PEI) [107] and polyethylene glycol (PEG) [103], to form complexes with DNA before the 
encapsulation process. This provides some protection, and in the case of PEG, it also allows 
for dissolution in organic solvents such as dimethyl sulfoxide (DMSO) [108].  
To avoid the shearing of the emulsion-solvent evaporation technique all together, there has 
been one report of the successful encapsulation of pDNA in PLGA NPs with the use of the 
nanoprecipitation method [109]. This method does not require the use of sonication or 
homogenization to create particles, they develop spontaneously, but the method does require 
the use of an organic solvent [110]. 
Like other endo-/phago-cytosed NPs after internalization, DNA-NPs will travel through the 
endo-/phago-lysosomal pathway where they are subsequently degraded. A prerequisite for 
treatment will be the escape of intact DNA to the cytosol, where it can translocate to the 
nucleus for transcription [111]. NP/pDNA escape from the endo-/phago-somal compartment 
is a highly debated topic but most agree it is necessary for the DNA, in some way, to escape 
the detrimental environment of the endo/phago-lysosome [84, 111]. In a highly cited paper by 





what they call a “selective reversal of the surface charge of NPs (from anionic to cationic)”. 
When cationic, the NP will interact with and destabilize the membrane of the endo-lysosome 
and escape to the cytosol [112]. The results of our group do not agree with this interpretation 
of Panyam and colleagues; in our results the NPs with RIF and the fluorescent dye coumarin-
6 remain in phagolysosomes where the polymer is degraded (Kalluru et al., in prep.). 
However, the fact remains that in the case of DNA-NPs some of the free DNA must be able to 
cross the membrane of the endocytic compartment and enter the nucleus in order to be 
expressed. Specific chemicals are often included in the NP formulation to facilitate this 
process. Usually this compound has a buffering capacity at the acidic pH of the endo-/phago-
lysosomal compartment. An example of such is PEI, which works as a “proton sponge”, 
causing osmotic swelling and subsequent disruption of the membrane [113, 114].  













2 Aims of study 
This Master’s thesis can be separated into two parts: (1) experiments related to improvement 
of TB drug therapy using the M.marinum-zebrafish embryo model system, and (2) 
encapsulation of plasmid DNA encoding an antimicrobial peptide. 
In TB drug therapy my aims were to: 
 Predict the treatment outcome in using RIF-NPs in the M.marinum-zebrafish embryo 
model system, namely identify which concentrations cause toxicity and can eradicate 
the bacterial infection. 
 Evaluate the anti-mycobacterial effect of thioridazine, alone and in combination with 
traditional antibiotics, in the M.marinum-zebrafish embryo model system. 
 For pDNA-encapsulation my aims were to: 
 Establish a protocol for encapsulation of plasmid DNA by use of the nanoprecipitation 
method. 
 Characterize the NPs produced and thereby establish protocols for this purpose. 
 Establish pDNA-NP therapy in mycobacterium-infected macrophages and 


























3 Materials and methods 
3.1 Zebrafish maintenance and care 
Approximately 100 Nacre -/- strain embryos were received from Darren Gilmour (EMBL, 
Heidelberg, Germany) and grown till adulthood in Peter Aleström’s zebrafish facility at the 
Norwegian School of Veterinary Science. The adult fish were then brought to the Department 
of Molecular Biosciences (University in Oslo) and put in an Aquatic Habitats Benchtop 
Aquaria Rack System (Aquatic Habitats, Apopka, FL, USA) to start our fish facility. This 
system keeps the water well aerated and at a constant temperature of 28°C. Each day, 
approximately 10 % of the tank-water is exchanged for fresh system water and the light/dark 
cycle in the room is 12:12 hours. The fish are fed three times a day; once with SDS 400 dry 
food (Lillicobiotech, Horley, UK) and twice with brine shrimp.  
 
The zebrafish can be bred every two weeks. The day before breeding, breeding tanks need to 
be set up: the bottom of the tanks are covered with a single layer of marbles; the tanks are 
filled with fresh system water and placed in a water bath to keep a constant temperature of 
28°C; and males and females (3 and 2, respectively) are placed in the tanks separated by a 
splitter and kept overnight. Zebrafish males are slender and have a torpedo-shaped body and 
they tend to chase females early in the morning before they breed. Females are more easily 
distinguished, as they are typically fat with eggs, which can easily be observed due to their 
transparent skin (Figure 6). Zebrafish are photoperiodic and breed at dawn. So, in the 
morning, before the light cycle begins, the splitters in the breeding tanks are removed and 
Figure 6: Adult zebrafish of the nacre strain. Its 
transparent skin allows us to readily identify this 
fish as female. Image taken from 
http://www.carolina.com/product/155590.do 
  




spawning takes place for approximately two hours. After spawning, the fish are returned to 
their tanks in the rack and the embryos are collected. Up to 200 eggs can be produced per pair 
of fish. Collected embryos are kept in embryo water
1
 in an incubator at 28°C and the embryo 
water is changed every day. The embryos will naturally escape the chorion themselves; 
however, this is undesirable as the chorion material is a haven for bacteria. Therefore, the 
embryos are manually dechorionated approximately 30 hours post fertilization with fine 
jeweler’s forceps (Dumont No.5). 
For fish experiments we either breed nacre zebrafish ourselves (as described above) or wild-
type embryos are bought from Peter Aleström’s zebrafish facility at the Norwegian School of 
Veterinary Science in Oslo. 
3.2 Culturing M.marinum 
The following protocols were adapted from the work of Cosma et al. 2006 [115] and Gao et 
al. 2005 [63]. 
Our group now has several genetically manipulated strains of M.marinum, but mainly either 
red or green fluorescent bacteria are used for infection studies. For my experiments, only red 
fluorescent bacteria have been used. The bacteria were generously supplied by Monica 
Hagedorn at EMBL in Heidelberg, Germany, and they are the human isolate strain ATCC 
#BAA-535, also called M strain, which carry a construct containing the fluorescent protein 
DsRed and a kanamycin resistance cassette.   
M.marinum grows optimally in vitro at temperatures between 30 to 32°C, has a generation 
time of 6 to 8 hours in the mid-log phase of growth, and has a biosafety requirement of BSL-
2. M.marinum is aerobic and it is a photochromogen, meaning its physiology and 
biochemistry varies in light versus dark; and M.marinum grows optimally in the dark. 
M.marinum can be cultured on both solid and in liquid medium, as I will describe. And I will 
also describe methods for long-term storage.  
For culturing in liquid medium, 20 ml 7H9 medium (BD, Franklin Lakes, NJ, USA) 
supplemented with 40 g/ml kanamycin (Sigma-Aldrich, St. Louis, MO, USA) and ADC 
(from here on called 7H9-kan) is aliquoted into a sterile 100 ml glass screw-top reagent bottle 
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and warmed up to approximately 31°C. A vial of frozen M.marinum-DsRed is thawed on ice 
for 15 – 20 min and the amount needed is inoculated into the pre-warmed medium. The 
inoculation amount depends mainly on how quickly one needs the bacteria to reach the 
appropriate optical density at 600 nm (OD600). According to a growth curve of M.marinum 
that I made (Figure 7), inoculating 1 µl frozen bacteria gives bacteria in the mid-log phase of 








Figure 7: Growth curve of M.marinum-DsRed taken from frozen stock. 
If the bacteria are needed faster, a higher inoculation volume can be used. The disadvantages 
of this are: (1) the culture will contain a higher percentage of bacteria originating from the 
frozen stock, some of which may not be viable; and (2) the frozen stock will be used up more 
quickly.  
Since M.marinum mostly grows in clumps or aggregates, it is important to de-clump the 
bacteria properly, which can be done in several ways; here we use a syringe fitted with a 
needle small enough to break up the clumps (22 G needle, BD). The OD600 needs to be 
measured directly after addition to the spectrophotometer cuvette to avoid the effects of 
possible sedimentation.    
After inoculation the lid of the bottle is tightened and the bottle placed in a shaking incubator 
at 31°C and 100 rpm, in the dark. (The micro-oxygenation under the shaking conditions is 























For culturing on solid medium, transfer 100 µl bacterial suspension to a 7H10 (BD) agar plate 
supplemented with 40 µg/ml kanamycin and ADC (from here on called 7H10-kan), that has 
been pre-warmed in a 31°C incubator. Use a disposable spreader to spread the bacteria evenly 
across the agar surface. One can also dip an inoculating loop in the suspension and spread it 
on the agar plate. The plates are placed bottom-side-up in an incubator set at 31°C, and left 
for 5 to 7 days until colonies appear. 
 
If needed, both liquid and solid cultures can be stored short-term. Liquid cultures can be 
stored at room temperature, in the dark, for 2 months. The same applies for solid cultures; the 
agar plates can be sealed and stored at room temperature, in the dark, for 2 months.  
For long-term storage one can prepare a frozen stock: 10 ml of the confluent culture (mid- to 
late- log phase) is transferred to a conical tube and centrifuged for 10 min at 2700 x g at room 
temperature. The supernatant is discarded and the pellet re-suspended in 10 ml freezing 
medium
2
. The solution is divided into 1-ml aliquots in cryo-vials and stored at -80°C. Under 
these conditions M.marinum remains viable for over 20 years.  
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Figure 8: M.marinum cultured on solid 
medium (7H10-kan agar). Colonies 
have a rough morphology, are 
irregularly shaped at the edge and waxy 
as a whole. These colonies are colored 
red due to the expression of DsRed.  




3.3 Infection of zebrafish embryos with M.marinum 
This infection protocol was largely established by David Westmoreland for his Master’s 
thesis. Else wise, this protocol was adapted from the work of Cosma et al. 2006 [115].  
There are two main locations for injection to choose from: the Duct of Cuvier (1) and the 
caudal vein (2) (Figure 9). Both injection sites are in the blood flow and the crucial 
differences are the time at which these injections can be performed and the level of difficulty. 
The caudal vein injection is the more difficult of the two but it has the advantage that it can be 
performed at 30 hours post fertilization (hpf), and will therefore give you more time for your 
experiments, while the Duct of Cuvier is available for injection after 48-56 hpf, the time it 
takes for the yolk sac circulation to form. Injection fluid is always injected the same direction 
as the blood flow. 
When the bacterial culture has reached the appropriate OD600 for infection (0.8 – 1.5), it is 
beneficial to check the fluorescence of the bacteria in a fluorescence microscope. This tells 
you something about the health of your culture. At the same time it is also advisable to check 
for contamination!  
Capillaries of borosilicate (without filament, outer and inner diameter of 1.00 and 0.78 mm, 
respectively, length of 100 mm, Harvard Apparatus, Holliston, MA, USA) were used to make 
needles by using a needle puller (P-97 Flaming/Brown micropipette puller, Sutter Instrument, 
Novato, CA, USA) at the following settings: pressure – 500, heat – 610, pull – 40, velocity – 
50, and delay – 110.  
Figure 9: Schematic of zebrafish larvae with arrows indicating the two main injection 









Typically 1 ml bacterial culture is taken out and spun down at 17,000 x g for 2 min. The 
supernatant is removed and the pellet is re-suspended in 1 ml pre-warmed 2 % 
polyvinylpyrrolidone, PVP (Merck Millipore, Billerica, MA, USA) (the PVP prevents the 
bacteria from aggregating during injection). This washing step is repeated. If the initial OD is 
appropriate for injection, one can re-suspend the pellet in 1 ml 2 % PVP. The final OD is 
measured against a 2 % PVP blank to make sure the OD is still above 0.8. If too many 
bacteria have been lost during the process, one can take a larger aliquot of liquid culture or 
reduce the amount of PVP to re-suspend in. When a satisfactory OD has been achieved, the 
bacterial solution is passed through a 27 G needle (BD) to de-clump the bacteria before 
injection. 20 % Phenol red (Sigma-Aldrich) is added to the suspension to create a 1 % 
solution (1 µl phenol red per 20 µl bacterial suspension), this to help visualize the injection. 
The borosilicate needle is loaded with 5 µl of the bacterial suspension containing phenol red, 
using a needle-loading pipette tip (Eppendorf, Hamburg, Germany). The needle is attached to 
the micromanipulator (Narishige, Tokyo, Japan) and pressure controller (FemtoJet, 
Eppendorf), and the nitrogen gas and pressure controller is then switched on.  
A petri dish lid is filled with mineral oil (Sigma) and the injection volume is adjusted to 
approximately 1 nl, as described by Rosen et al. 2009 [116].  
Before infections, one injection is performed in a drop of PBS on a 7H10-kan agar plate to 
estimate the CFU of the injection volume. This procedure should be performed at intervals 
throughout the experiment to determine the average amount of bacteria which are injected. 
When ready for infection, 2-day old embryos are taken from the 28°C incubator and 
transferred to a tricaine (Argent Laboratories, Redmond, WA, USA) bath (252 µg/ml, pH ~7) 
to be anaesthetized. After 1-2 min the embryos are transferred to a 2 % agarose (Invitrogen, 
Life Technologies, Paisley, UK) injection plate and the excess water is removed in order to 
immobilize them while injecting. The micromanipulator is then used to move the needle to 
the desired injection site and the injection is performed. The presence of phenol red in the 
blood stream will be an indicator of a successful injection (Figure 10).  






Using a pipette, the injected embryos are then transferred into a new dish containing fresh 
embryo water and eventually placed in the incubator.     
The embryos could then be used for monitoring survival or could be picked out at 
predetermined time-points for gene expression analysis by quantitative PCR. When the latter 
was the case, the embryos were euthanized in tricaine, placed in the appropriate amount of 
RNAlater
3
 (as recommended by the manufacturer, Ambion, Life Technologies, Paisley, UK), 
and stored at 4°C until they were ready for use. In this case embryos were collected at 2, 5, 8 
and 24 h, and 3 days pi for examination of gene expression. 
Gene expression analyses were performed by Henning Fedders in Matthias Leippe’s Group at 
the Christian Albrechts University in Kiel, Germany, as a part of our collaboration with them. 
The genes of interest were the genes encoding NK-lysins 1-4 in the zebrafish. Comparisons 
were made between infected embryos and control embryos injected with PBS.  
                                                 
3
 RNAlater is a reagent that stabilizes and protects RNA in tissue samples. 
Figure 10: By using phenol red one can clearly separate the successful injections from the unsuccessful. 
Figure courtesy of David Westmoreland. 
 




3.4 Infection of adult zebrafish with M.marinum 
This procedure is largely based on the protocols supplied by Cosma et al. 2006 [115] and 
Arturas Kavaliauskis, 2011 [117].  
Bacteria were prepared as stated above. 
The acquired amount of fish were collected from the fish facility and transferred to a separate 
facility to avoid any contamination. One by one, fish were transferred to a tricaine bath (252 
µg/ml). When the fish rolled onto their sides they were ready for injection. They were placed 
belly-up in a mounting sponge to hold the fish in place and to keep them moist. Injection was 
performed in the peritoneal cavity, just below the pelvic fin. The needle was inserted only so 
far in as to cover the beveled tip of the 27 G needle and approximately 10 µl of PBS or 
bacterial solution was injected. After injection the fish were transferred to a recovery tank 
before they were placed in new tanks with fresh water. 
From there on the fish could be monitored for survival or be taken out for gene analysis at 
given time points, as described below. 
3.5 Dissection of organs for gene expression 
analysis 
In large, this procedure was executed as explained by Gupta et al. 2010 [118]. 
Shortly, the fish were euthanized with tricaine and pinned to the dissection plate on their side.  
The skin and muscle were then removed using dissecting scissors (Allgaier Instrumente, 
Frittlingen, Germany) and forceps (Dumont no5), to expose the internal organs. The organs of 
choice (spleen, liver, kidney and intestinal tract) were then removed and placed in an 
appropriate amount of RNAlater (as recommended by the manufacturer) and stored at 4°C 
until they were ready for use. 
 
 




3.6 Enumeration of M.marinum from infected 
embryos 
To determine the bacterial load during an infection, and eventual treatment, one can do a CFU 
enumeration. Embryos were selected at random.  
The following protocol is an adaption of what is reported by Cosma et al. 2006 [115]. 
500 µl of embryo water with 20 µg/ml kanamycin was aliqouted into eppendorf tubes, one for 
each embryo. Infected embryos were transferred to one tube each and left to soak for 1 h at 
room temperature, this to reduce the contamination from normal flora. After an hour the 
embryo water was removed and replaced with 500 µl 200 µg/ml tricaine and incubated for 1 h 
on ice, this to euthanize the embryo. The tricaine solution was then removed and replaced 
with 150 µl 1x trypsin-EDTA (Sigma-Aldrich) and the samples were incubated for 1 h at 
30°C. After an hour the embryos were homogenized with the use of a micropestle and 
returned to 30°C for half an hour more. After that, the samples were vortexed every half to 
whole hour; until there were no visible signs of embryo debris (takes 4 – 5 h).  
When digestion was complete, 30 µl 1x PBS and 20 µl 1 % Triton X-100 (Sigma-Aldrich) 
was added to each tube and vortexed before they were placed in a water bath ultrasonicator 
for 10 min. 
The samples were consolidated in a table top centrifuge before the entire volume, 200 µl 
(unless dilution series are needed), was spread evenly upon 7H10-kan agar plates 
supplemented with various antibiotics (amphotericin B, polymixin B sulfate, trimethoprim, 
carbenecillin (Sigma-Aldrich) to prevent the growth of contaminants from the embryo.  
Plates were incubated at 31°C until colonies could be seen (4 – 5 weeks), and they were 










3.7 Rifampicin and thioridazine bath experiments 
RIF bath experiments 
This protocol was adapted from the work done by Adams et al. 2011 [119]. 
For these experiments different concentrations of RIF (Sigma-Aldrich) were used: 100, 320, 
500 and 640 µg/ml. Embryos were kept in petri dishes, which typically take 20 – 30 ml of 
liquid. RIF solutions were made for three days at a time, making the final volume 90 ml.  
These experiments consisted of 8 groups in total (Figure 11). 
 
RIF has low solubility in water and therefore had to be dissolved in DMSO (Sigma-Aldrich) 
(1 % of total volume) before adding it to the embryo water. 
For three days one needs 90 ml RIF-water for the groups 100 and 320 µg/ml, subsequently 9 
and 28.8 mg RIF was dissolved in 0.9 ml DMSO, respectively
4
.  
For three days one needs 180 ml RIF-water for the groups 500 and 640 µg/ml, subsequently 
90 and 115.2 mg RIF was dissolved in 1.8 ml DMSO, respectively
3
. 
0.9 and 1.8 ml dissolved RIF was then added to 89.1 and 178.2 ml embryo water, to bring to a 
final volume of 90 and 180 ml, respectively. 
Solutions were kept at 4°C and protected from light, as RIF is light sensitive.  
                                                 
4
 For calculations, see Appendix 







Figure 11: Schematic of experiment set-up. 




Infected and uninfected embryos were transferred to the RIF baths 1 day post injection, dpi (3 
days post fertilization, dpf), and the water was changed every day in combination with 
observing embryo survival. 
TZ bath  
The principle for this procedure is the same as described above, only TZ (Sigma-Aldrich) was 
used instead of RIF.  
Again, 90 ml solutions were made, three days at a time with concentrations of 0.01, 0.05, 
0.08, 0.1, and 0.5 µg/ml TZ. TZ is water soluble so 9, 45, 72, 90 and 450 µl of TZ stock 
solution (0.1 mg/ml), was each added to 90 ml embryo water. 
Uninfected embryos were transferred to the TZ bath 3 dpf (the same time point as when the 
embryos were infected) and the water was changed daily while monitoring embryo survival. 
RIF and TZ bath experiment 
The principles are again the same as described earlier, the only difference is that here, RIF 
and TZ were used in combination (Figure 12).  
One concentration of RIF was used, 320 µg/ml, and two concentrations of TZ, 0.01 and 0.1 
µg/ml. With the addition of controls that makes 7 groups (Figure 12). The 90 ml solutions of 
320 µg/ml RIF were made as described above, and the appropriate amount of TZ, also noted 
above, was added to the solutions.  
Infected and uninfected embryos were transferred to the appropriate water baths 1 dpi/3 dpf, 
and the bath water was changed daily. Embryo survival was subsequently monitored.  
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Fluorescence imaging was performed on a Leica DM IRBE microscope (Leica, Wetzlar, 
Germany). Image processing was performed with the ImageJ software. 
3.8 Nanoparticle preparation 
Nanoprecipitation 
First developed by Fessi et al. in 1989 [110], this method is relatively easy and it is performed 
in just one step (Figure 13).  
 
 
Because most polymers are water-insoluble, this technique is most suitable for encapsulation 
of hydrophobic compounds but many advances have been made in modifying the traditional 
method for use with hydrophilic compounds as well [88, 120].  
Two miscible solvents are required; ideally the polymer and therapeutic agent of interest 
should be dissolved in one, the solvent; but not in the other, non-solvent. As soon as the 
polymer-containing solvent has diffused into the non-solvent medium, the polymer 
Figure 13: Nanoprecipitation procedure. The polymer-containing solvent is added 
drop-wise to the non-solvent and nanoparticles are formed immediately. 




precipitates, and drug entrapment is immediate. This phenomenon is called the Marangoni 
effect and particles with a size range of 100 – 300 nm are usually obtained. [120] Compared 
to emulsion-solvent evaporation techniques, nanoprecipitation is a mild technique. Here the 
shearing forces of homogenization and sonication can be avoided, a crucial factor when 
working with DNA and proteins.  
The following procedure was adapted from the nanoprecipitation procedure described by Niu 
et al. 2009 [109]. 
Approximately 200 µg pDNA (pCMV-CAMP-GFP, Origene, Rockville, MD, USA) was 
taken out from a Maxiprep (Quiagen, Düsseldorf, Germany) solution and precipitated with the 
use of ethanol. Specifically, 5 µl 125 mM EDTA was added per 20 µl DNA solution. An 
appropriate amount of 96 % ethanol was added to create a 70 % solution and the sample was 
left to incubate on ice for 10 min. The sample was centrifuged at 6,000 x g, at 4°C for 30 min 
to pellet the precipitated DNA. The supernatant was then removed and the precipitated DNA 
could be used for encapsulation. 
20 mg PLGA (Resomer RG 502H, Evonik Industries, Essen, Germany) and ~200 µg pDNA 
was dissolved in 1 ml DMSO and added to 20 ml 0.5 % Pluronic F-127 (Sigma-Aldrich) 
aqueous solution on a magnetic stirrer (600 rpm) using a syringe fitted with a 22 G needle at a 
speed of 0.5 ml/min. Nanoparticle formation is immediate, as can be seen by the milky blue 
color the solution obtains (Figure 14). The nanoparticle solution was left to stir for 5 h to 
facilitate the evaporation of DMSO.  
 
 
Figure 14: Successful nanoprecipitation can readily be 
seen by the milky blue color the solution obtains as 
more NPs are formed. To the left one can see water. 
The sample in the middle contains 20 mg PLGA-NPs 
and the sample to the right contains 40 mg PLGA-NPs. 
The intensity of color therefore increases with an 
increasing amount of polymer.  




The nanoparticles can then be collected by centrifugation (25,000 x g, 4°C, 30 min) and 
subsequently freeze-dried or they can be concentrated with the use of centrifuge tubes fitted 
with filters (Spin-X UF, Corning Inc, Corning, NY, USA), at 9,000 x g for 30 min, and stored 
in aqueous solution at 4°C. 
To make fluorescent particles, the same procedure can be followed only instead of pDNA, 
0.05 mg of the fluorescent dye, coumarin-6 (Sigma-Aldrich), was added to the polymer 
solution prior to precipitation.  
3.9 Nanoparticle characterization 
Characterization and size estimation of the NPs was done by transmission electron 
microscopy (TEM) (Philips, CM100).  
Before visualization, nanoparticles were adsorbed to a formvar/carbon-coated copper grid and 
subjected to negative staining.  
The grids for electron microscopy were placed in a drop of the NP solution for 1 – 2 min and 
washed in distilled water three times before it was placed in a drop of 4 % uranyl acetate 
(Sigma-Aldrich) for 1 min. After incubation the grid was removed, excess liquid was 
removed with a filter paper and the grid was left to dry. When dry, imaging could be 
performed.    
3.10  DNA extraction from NPs 
To check the integrity of and to quantify encapsulated pDNA, the pDNA must be extracted 
from the NPs. This procedure was adapted from Niu et al. 2009 [109]. 
500 µl chloroform (VWR, BDH Prolabo, Lutterworth, England) was added to 100 µl 
concentrated NP solution diluted in 400 µl 1 x TE buffer. The solution was briefly vortexed 
before it was left to rotate end-over-end for 1 h at room temperature. After 1 h the solution 








3.11 DNase I digestion analysis 
NPs have been shown to protect encapsulated DNA from nuclease attack with the use of 
DNase I [104, 105]. This procedure is not only good for evaluating the protective abilities of 
NPs but also for the direct evaluation of whether or not the pDNA has been encapsulated at 
all. DNase I and the reaction buffer were acquired from the RNase-free DNase kit from 
Quiagen. 
20 µl concentrated NP solution was added to 70 µl reaction buffer. 10 µl DNase I (~2.7 
Kunitz units/µl) was then added to the sample and the sample was incubated at 37°C for 30 
min. 10 µl 0.5 M EDTA, pH 8, was added to stop the reaction and the sample was incubated 
for 5 min at 65°C to inactivate the enzyme. This solution could then be used for subsequent 
analyses. 
3.12 Analysis of DNA integrity 
The following procedure was adapted from Niu et al. 2009 [109]. 
Extracted DNA was analyzed by gel electrophoreses on a 0.8% agarose gel.  
0.4 g agarose (Invitrogen) was dissolved in 50 ml 1 x TAE buffer. Before casting the gel, 5 µl 
GelGreen (Biotium, Hayward, CA, USA) was added to the solution, as recommended by the 
manufacturer, to visualize DNA. 
A 1-kb ladder (Invitrogen) was used and a 10 x loading buffer.  
The gel was run at 90 V for 30 min and visualization was performed in a UV transilluminator 
(UVP, Upland, CA, USA).  
3.13 Quantification of encapsulated DNA   
To quantify the amount of DNA that is encapsulated, through DNA extraction, the PicoGreen 
(Invitrogen) reagent can be used. It is a fluorescent nucleic acid stain that binds double 
stranded DNA (dsDNA) and it can quantify as little as 25 pg/ml. The following procedure 
was acquired courtesy of Monica Hongrø Solbakken at Centre for Ecological and 
Evolutionary Synthesis, CEES, UiO. 




To quantify the fluorescence from the PicoGreen reagent a FluoStar Optima (BMG Labtech, 
Ortenberg, Germany) microplate reader was used in addition to the Optima software. The 
microplate reader will apply 100 µl of the reagent to the wells for us but before one starts, one 
has to wash the system two times with distilled water.  
A standard curve for the DNA solution needs to be made for every run, either the λ DNA 
supplied with the PicoGreen kit or preferentially the dsDNA one is quantifying. When using λ 
DNA a 2 µg/ml solution is made from the 100 µg/ml solution in the kit. Subsequently, 
concentrations of 1, 0.2, 0.02, 0.002 and 0 µg/ml are made to make up the standard curve and 
100 µl of each is applied to a black 96-well plate (Greiner Bio One, Frickenhausen, Germany) 
in triplicate. All of these concentrations give us 200, 100, 20, 2, 0.2 and 0 ng DNA/well, 
respectively, and dilutions are made with 1 x TE buffer. 
Before preparing the sample, it is beneficial to estimate the concentration of one’s sample 
using Nanodrop or some equivalent, because the PicoGreen has an optimal binding range 
between 25 pg/ml and 1000 ng/ml.  
The sample is diluted in 1 x TE buffer. The appropriate dilutions can range from 1:100 to 
1:20,000, where the higher dilutions are more suitable for Maxiprep products. 100 µl of the 
samples are added to each well in triplicates. 
The PicoGreen reagent should be diluted 200 x and enough solution should be made as to 
apply 100 µl to each well. In addition, one should account for the 1 ml needed to wash 
through the system before measurements are started. PicoGreen is light-sensitive and should 
therefore always be protected from light.  
When ready, the microplate is put in the microplate reader, the system is primed once with TE 
buffer and once with the PicoGreen solution. When all settings are appropriate, measurements 
can start. The microplate reader applies 100 µl to each well, lets the reagent incubate for 5 
min and measures the fluorescence.  
The reader is saturated at 65,000 fluorescent units s
-1
 so measurements close to this value 
should be discarded. This means that the least diluted sample must be placed at the end of the 
reading as not to saturate the reader in the beginning and skew all subsequent readings. 
Measurements at 3,000 fluorescent units s
-1
 should also be discarded, as this is too low, 
measurements should preferentially be around 10,000.  
 





Statistics were performed on the survival experiments using the Minitab program (provided 
by the University in Oslo). A Log-rank test was done using Kaplan-Meier values to provide p-

























4.1 Zebrafish studies 
As discussed earlier, M.marinum-infected zebrafish embryos have proven to be a good model 
system for M.tb infection in humans and the embryos will typically die from illness 6 – 8 dpi, 
depending on the bacterial load and individual susceptibility. The embryos’ susceptibility to 
M.marinum infection is shown in Figure 15. 
 
 
We also showed that the injection itself was not the reason for deaths among the embryos by 
injecting PBS in parallel with bacteria. The PBS injected group showed the same survival as 
the control group (data not shown).  
4.1.1 Rifampicin bath treatment 
In doing these experiments we wanted to establish which concentrations of RIF eradicate the 
bacteria and if toxicity would affect embryo survival. The following results were to help us 
get an idea of how much RIF we need to encapsulate and what amount of NPs need to be used 
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Control  
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Figure 15: Survival experiment where embryos were infected with M.marinum at an OD600 
~ 0.8. Embryo survival started decreasing at day 7 and by day 10 all the infected embryos were 






Wild type zebrafish embryos were infected with M. marinum-DsRed at an OD600 of 0.962 (on 
average 25 bacilli per injection) 2 dpf and placed in baths containing different concentrations 
of RIF 1 dpi. Depicted in Figure 16 are the results obtained from one of the bath experiments, 
which I will subsequently refer to as experiment number 1.  
The infected control and the 100 µg/ml groups could be found at the bottom of the graph with 
the lowest percentage of embryo survival over a period of 11 days of treatment. Indeed, 100 
µg/ml RIF was a sub-optimal concentration and was not expected to facilitate a bactericidal 
effect. The 320 µg/ml group (MEC, minimum effective concentration
5
 established by Adams 
et al. 2011 [119]) showed poor bactericidal activity with an embryo survival of approximately 
30 %. The best therapeutic concentrations were 500 and 640 µg/ml, which showed approx. 50 
% and 70 % embryo survival, respectively, and these groups were not significantly distinct 
from the uninfected control group. The 500 and 640 µg/ml uninfected control groups were 
also deemed non-significant by statistics, and together with the control group showed approx. 
80 % survival.  
  
 
The experiment was repeated, in the hope of being able to confirm the results obtained in this 
first experiment. However, this second experiment (experiment number 2) was not as 
                                                 
5
 Minimum effective concentration is the lowest concentration of drug that is non-toxic and normalizes host 
survival when administered to infected zebrafish embryos within 1 dpi [121]. 
Figure 16: Survival experiment Nr. 1 with different concentrations of RIF. Asterisks mark 































Control, 500 µg/ml 
640 µg/ml 








successful as the previous one due to problems during the injection of bacteria. Clogging of 
the needle led to variable and lower bacterial loads. Even so, one could see the start of a 




Also in this experiment the uninfected control groups showed 80 – 90 % embryo survival, 
together with the groups treated with 500 and 640 µg/ml RIF; again, there was no significant 
difference between the treated groups and the control group. The groups treated with 100 and 
320 µg/ml RIF showed the same survival, ~65 %, and the untreated infected control group 
showed that only 20 % of embryos survived the 11 day monitoring period. The only group 
deemed significant in this experiment was the infected control group, making this experiment 
inconclusive, but I will later argue that a delayed trend could be seen in this experiment.   
Fluorescence microscopy 
In addition to monitoring survival, the bacterial load could be monitored directly using 
fluorescence microscopy (Figure 18). For every time-point: 3, 5, 7 and 9 dpi, three randomly 
chosen embryos were taken out for imaging. Imaging was performed on embryos from 
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Figure 17: Survival experiment Nr. 2 in the presence of different RIF concentrations. WT 
embryos were injected with M. marinum-DsRed at an OD600 of 0.954. Groups had n ≥ 16. 






In Figure 18, one can see that in all groups the day 3 embryos did not show many bacteria. 
With this bacterial load, 3 dpi was too early to visualize granulomas but one could clearly see 
the increasing amount of bacteria over the days in fish from the infected control and 100 
µg/ml groups. In the 320 µg/ml and 500 µg/ml groups, one could see that the load did not 
increase to the same level as the infected control group, but whether a plateau was reached or 
a decrease in bacterial load was achieved, was hard to say. At 9 dpi persisting bacteria could 
be seen in these two groups and in the 640 µg/ml group, but in the latter one had to look hard 
to find any bacteria.  
Enumeration of bacterial load 
A third way of monitoring infection was through CFU, where the infecting bacteria were 
isolated from tissue and plated so the colonies could readily be counted. The CFU results 
from experiment Nr. 1 are presented in Table 1, along with the standard errors.  
 
Days post 
infection Infected 100μg/ml 320μg/ml 500μg/ml 640μg/ml 
3 9±7 0±0 0±0 0±0 1±0 
5 19±10 0±0 21±21 0±0 0±0 
7 26±26 2±1 1±0 0±0 0±1 
9 967±376 1350±1020 1±1 3±2 1±1 
 
The CFU for the infected controls showed a steady, but low level increase over the 
experimental period, before it had increased dramatically by day 9. The 100 µg/ml group also 
showed a dramatic increase by day 9, but an increase during day 3 – 7 was not observed. The 
CFU for the 320 µg/ml group did not show the same trend as the infected group, and the 
results for 500 and 640 µg/ml were difficult to interpret, as too few bacterial colonies were 
observed to give us conclusive results. It is generally accepted that to obtain statistically valid 
data, the agar plates should contain between 30 and 300 colonies [62]; making these results 
inconclusive.   
CFU was not obtained from RIF bath experiment nr. 2 due to the inconsistencies associated 
with this method.  
Table 1: CFU from RIF bath experiment Nr. 1. Randomly, triplicates of embryos were removed 






Figure 18: Visualization of bacterial load during infection with M. marinum-DsRed. Arrows indicate 
individual or small groups of bacteria. The thick arrow indicates auto-fluorescence of the intestine. 
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4.1.2 Thioridazine tolerance 
Before we could use TZ in conjunction with RIF for the treatment of M.marinum-infected 
zebrafish embryos, the toxicity of this compound needed to be evaluated.  
Wild type embryos were placed in water baths containing different concentrations of TZ, 3 
dpf. As noted above, based on the results obtained from experiments with macrophages we 
knew that 0.1 µg/ml should be an effective concentration and we knew the upper limit would 
be 0.5 µg/ml, since this is the concentration used in treatment of psychotic disorders and we 
want to avoid possible effects on the central nervous system. During a pilot experiment it was 
observed that 0.1 µg/ml TZ had a toxic effect on embryos (results not shown), therefore lower 
concentrations were in addition chosen for this experiment. 
Figure 18: Visualization of bacterial load during infection with M. marinum-DsRed. In this figure we 
have a typical example of how different the infection can be in different individuals. In the left picture at 
day 7 one can see an abnormally high bacterial load, as opposed to the low bacterial load visualized in the 









As can be seen in Figure 19, 0.1 and 0.5 µg/ml TZ showed significant toxicity; ~40 % and 
>90 %, respectively, of the fish died during the 10 day monitoring period. 0.01 and 0.05 
µg/ml TZ showed little to no toxicity but 0.08 µg/ml showed more toxicity, killing almost 20 
%. The data for the 0.08 g/ml group were deemed significantly elevated in comparison to the 
control group.   
4.1.3 Rifampicin and thioridazine bath treatment 
Based on the results obtained above we selected the concentrations 0.01 and 0.1 µg/ml TZ for 
more detailed evaluation. Even though 0.1 µg/ml showed significant toxicity, our rationale 
was that when encapsulated in NPs, the eventual goal, the toxicity would be predicted to be 
reduced since such treatment no longer is systemic but targeted.  
Survival study 
Wild type embryos were infected with M.marinum-DsRed at an OD600 of 0.8 and placed in 
treatment baths 1 dpi; the results are shown in Figure 20. As expected, the 0.1 µg/ml group 
showed significant toxicity. 0.01 µg/ml TZ showed no bactericidal effect as the group had 
approximately the same survival rate as the infected control group. Contrary to previous 
































Figure 19: Toxicity of TZ monitored by survival. In contrast to the other survival experiments, 
the treatment period here is 10 days because a significant amount of controls died at day 11, 
leading to the exclusion of this time point all together. Asterisks mark the data determined to be 








was 80 %. Indeed, the data for this group was evaluated to be not significantly different from 
the control group. The embryos treated with RIF and 0.1 µg/ml TZ showed a survival rate of 
40 % and the group treated with RIF and 0.01 µg/ml TZ showed a survival rate similar to the 
group treated with RIF alone and the control group. The difference between these two groups 




Also in this study, we monitored the infection visually by fluorescence microscopy. At the 
same time-points as before: 3, 5, 7 and 9 dpi, three embryos were randomly chosen for 
imaging. The images for the groups in this experiment can be found in Figure 21.   
The infected controls showed a steady increase in bacterial load. The 320 µg/ml RIF group 
had some therapeutic effect, as seen earlier, but also here there was some variability as seen at 
day 9; when one embryo showed a higher bacterial load than the others. For the 320 µg/ml 
RIF + 0.01 µg/ml TZ group the same therapeutic effect could be seen as for the group treated 
with RIF alone, but when using 0.1 µg/ml TZ together with RIF the therapeutic effect seemed 
to be greater due to the presence of less bacteria at 9 dpi. Unfortunately, it was difficult to see 
the difference between the 9 dpi fish in the 320 µg/ml group with the least bacteria and the 9 
dpi fish in the RIF + 0.1 µg/ml TZ group. The embryos treated with TZ alone did not show 





























320 µg/ml + 0.01 µg/ml 
320 µg/ml + 0.1 µg/ml 
0.01 µg/ml 
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Figure 20: Survival experiment in the presence of RIF and TZ. Asterisks mark the groups that 










Figure 21: Visualization of bacterial load during infection with M. marinum-DsRed. Arrows indicate 
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In parallel to the experiments with antibiotics described above, we initiated a series of 
experiments aimed at encapsulating pDNA encoding an anti-microbial peptide in 
nanoparticles. In order to be able to monitor the uptake of the NPs into cells, and eventually 
into the zebrafish, we also decided to encapsulate a hydrophobic green-fluorescent dye, 
coumarin-6.   
4.2.1 Increasing the average size of NPs 
In our first attempt in making NPs, following the protocol reported by Niu et al. 2009 [109], 
we realized the particles were very small (Figure 22).  
 
 
With the knowledge that macrophages preferentially phagocytose particles between 200 nm 
and 1000 nm and that this size range is the more effective for drug delivery, we set out to try 
to increase the size of the particles made by the nanoprecipitation method. 





Several factors in the procedure could be altered to affect NP size: polymer concentration, 
solvent/non-solvent ratio, type of solvent or non-solvent, surfactant, stirring rate, drop size 
and eventually drug to polymer ratio. One by one these factors were altered in the attempt to 
make bigger NPs and the results are listed in Table 2. 
 
 
As one can see above, changing these factors had little to no effect in producing sizes above 
200 nm. The one factor that stayed the same, the solvent, may be the factor that could 
effectively increase NP size. However, due to the fact that we were trying to encapsulate 
pDNA, we were limited to the use of DMSO so as not to compromise the delicate nature of 
DNA when associated with organic solvents. The fluorescent compound coumarin-6 is 
hydrophobic, so organic solvents could safely be used for its encapsulation. When DMSO 
was used as the solvent, particles with sizes similar to the ones presented in the table above 
were produced: < 200 nm, but when acetonitrile, MeCN, was used as the solvent, bigger 
particles were obtained; 50 – 320 nm (Figure 23). 
 
Batch Non-solvent S/NS ratio Polymer conc. (mg/ml) Pluronic F-127 (%) Rpm Size range (nm) 
1 H2O 0.05 20 0.5 600 50 - 170 
2 H2O 0.05 40 0.5 600 80 - 150 
3 H2O 0.05 20 0.5 450 50 - 120 
4 H2O 0.05 40 0.5 300 70 - 200 
5 H2O 0.05 40 0.5 100 70 - 180 
6 H2O 0.05 20 0.25 300 90 - 170 
7 H2O 0.05 20  -  300 70 - 130 
8 H2O 0.025 40 0.5 600 80 - 140 
9 H2O 0.25 20 0.5 600 80 - 160 
10 H2O 0.1 20 0.5 600 30 - 125 
11 Ethanol 0.05 20  -  600 70 - 200 
12 Ethanol 0.05 20 0.5 600 50 - 160 
13 H2O 0.05 20 1 (PVA) 600 60 - 115 






4.2.2 Encapsulation of pDNA 
Even though we failed to acquire NPs in the preferred size range, we continued our endeavor 
to encapsulate pDNA with the nanoprecipitation method. For encapsulation, a pCMV-GFP 
vector with the human cathelicidin, LL-37, as insert was used. If successful, GFP expression 
could then be monitored in vitro in BCG-infected macrophages and subsequently the effects 
of LL-37 expressed via the pDNA could also be monitored in both macrophages and zebrafish 
through the reduction in bacterial load. 
The first challenge we encountered was dissolving the DNA in DMSO. After performing a 
Mini- or Maxiprep, the extracted pDNA was eluted preferentially in water or TE-buffer. 
Mixing this solution directly with DMSO led to a reduction in the solution’s hydrophobicity 
and PLGA would therefore not dissolve properly, leading to failed nanoprecipitation. The 
appropriate amount of pDNA was therefore precipitated with ethanol to allow direct 
dissolution of the pellet in DMSO. We soon realized the pellet was hard to dissolve in DMSO 
alone so we started to dissolve the pellet first in 30 µl TE-buffer, pH 8, and then add the 1 ml 
of DMSO. With this procedure, the nanoprecipitation was successful but we then had to 
determine whether the pDNA was actually encapsulated or if it was free in solution. In Figure 
24 one can see that pDNA was present in the NP solution, both before and after DNA 
extraction with chloroform. 
 
Figure 23: Coumarin-loaded NPs 
made with MeCN as solvent produced 
NPs up to 300 – 400 nm in size. Scale 






Seeing that these results did not unequivocally tell us whether the pDNA was inside or 
outside our NPs, we used DNase I to eliminate potential non-encapsulated pDNA in the 
solution. The results revealed that, in fact, no pDNA could be extracted from the DNase I 
treated pDNA-NP solution, arguing, to our disappointment, that no pDNA was encapsulated 
(results not shown).     
Because of its hydrophilic nature, it was clear that DNA would rather be in water than in 
DMSO. We considered the possibility that the small amount of TE-buffer used to dissolve the 
DNA may have compromised the encapsulation process. We therefore sought to eliminate 
aqueous solutions from this step all together. We then went back to the original strategy of 
trying to dissolve the pDNA pellet directly in DMSO by heating the solution up to 
approximately 50°C during magnetic stirring. The pellet seemed to dissolve and the 
nanoprecipitation was successful. The results of DNase I treatment of these NPs can be seen 
in Figure 25. 
 
As shown in Figure 25, no pDNA could be detected in the DNase I treated pDNA-NPs, 
showing again that pDNA was not successfully encapsulated. To our disappointment, this 
problem remains to be resolved by others in our group. 
      
 
5 kb 
Figure 24: Agarose gel electrophoresis of pDNA-NPs and 
extracted pDNA. Lane 1 contains the pCMV-CAMP plasmid 
(7.1 kb) as a positive control. Lane 2 shows the extracted 
pDNA and lane 3 shows the pDNA-NP solution from which 
pDNA was extracted. Lane 4 contains a solution of empty NPs 
as a negative control.  
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Figure 25: Agarose gel electrophoresis of DNase I 
treated pDNA-NPs and extracted pDNA. Lane 1 contains 
the pCMV-CAMP plasmid as a positive control. Lane 2 
shows the pDNA containing NP solution and lane 3 
contains the extracted pDNA from that sample. Lane 4 
contains pDNA-NP solution that has been treated with 
DNase I, and lane 5 shows the extraction product from that 








4.3 Gene expression analyses 
Gene expression analyses were performed on both infected embryos and adults for NK-lysins 
1-4 but the results from both preliminary experiments were highly inconclusive. The 
























In this thesis I took advantage of the zebrafish-M.marinum model system established by the 
Ramakrishnan group in order to initiate a series of experiments aimed at improving therapy 
against M.tb. Our group has recently established the use of PLGA-NPs loaded with the 
antibiotic rifampicin (RIF). These NPs have been used to treat BCG-infection in macrophages 
and M.marinum-infection in zebrafish embryos to such a degree as to clear the infection 
(Kalluru et al. in prep., Fenaroli et al. work in progress). My strategy in advancing this 
progress was two-sided. First, I initiated experiments where the effects of the antibiotic RIF 
and the efflux pump inhibitor TZ, both alone and in combination, were examined in 
M.marinum-infected zebrafish embryos. The rationale here was that TZ would work in 
synergy with RIF to more effectively decrease, and hopefully eradicate, the bacterial load 
during infection. Second, given the increasing difficulty to treat drug-resistant M.tb strains, I 
sought to develop an alternative strategy: to deliver pDNA encoding anti-mycobacterial 
peptides to mycobacteria-infected cells.  
5.1 Antimicrobial peptides as therapy against M.tb 
Experimental work with peptides is expensive and the yield from production is usually low 
[16]. In addition, many exogenous peptides are sensitive to the physiological salt 
concentration in our bodies [18]. Thus, their short half-lives and toxicity [16], led us to prefer 
the idea of using pDNA encoding the peptides of interest for therapeutic studies. 
Amplification of the pDNA is cheaper and easier, and high yields can be obtained with the 
use of Maxi- or Giga-preps. Once expressed at the target site, the antimicrobial peptides 
present many theoretical advantages over antibiotics, as mentioned earlier. Briefly, those 
advantages include: activity against many different bacteria, including those that are drug-
resistant, and the unlikely acquirement of resistance.  
Four peptides were considered for use in therapy against M.marinum in zebrafish embryos: 
defensins, cathelicidin, NK-lysin, and Ci-MAM-A24. All of these show bactericidal effects 
against M.tb, making them good candidates for use [18, 25, 36]. A lot of thought was put into 
which peptides should be used in the beginning of my project and eventually we decided to 
use a commercially available construct for proof of principle; the pCMV-CAMP-GFP 





not native to zebrafish, we believe the peptide should still work as an anti-mycobacterial 
agent due to its known activity. LL-37 has been reported to be expressed in many different 
cells during M.tb-infection, where the highest levels were reported in alveolar macrophages 
[35]. This suggests that LL-37 plays an important part of the host’s defense against M.tb, and 
that increased presence of this peptide facilitates the killing of this pathogen. Thus, I expect 
that all anti-microbial peptides that show killing activity against M.tb should be effective 
whether they are native to the host organism or not.      
5.2 Nanoparticle-based therapy 
We believe that NP-based therapy will become increasingly important in future medicine and 
that this will help us overcome many of the obstacles in traditional medicine we are faced 
with today. As mentioned earlier, toxic side-effects, development of resistance, length of 
treatment, and frequency of dosing, are all negative features associated with TB treatment [6, 
87]. We believe all these characteristics can be avoided with the use of drugs encapsulated in 
NPs, as opposed to the free form (oral, injection, and aerosol). Indeed, results have shown that 
this is exactly what is achieved when using RIF-loaded NPs in treatment of TB. NPs are 
transported to the site of infection (no targeting is necessary since macrophage uptake is the 
default pathway) and will lead to a higher local concentration of drug [95]. This in turn 
prevents systemic toxicity and can prevent the emergence of drug resistance, while the length 
of treatment and the dosing frequency can be drastically reduced [97, 99], leading to lower 
costs for this treatment regimen.  
We are in the process of using RIF-NPs for the treatment of BCG-infection in macrophages 
and M.marinum-infection in zebrafish embryos, but we are also pursuing the possibility of 
encapsulating other anti-mycobacterial compounds, such as TZ and plasmid DNA that 
encodes anti-microbial peptides. We think that the use of RIF-NPs in combination with NPs 
loaded with additional anti-mycobacterial compounds could be a promising solution to 
effectively eradicate a mycobacterial infection.  
Concerning TZ, we believe the toxic side-effects that are often observed with this compound 
can be largely avoided by encapsulating the drug in NPs. These NPs would then deliver TZ 
directly to macrophages, as it does RIF, and targeted and sustained release would prevent the 





DNA-NPs can improve two important aspects as opposed to using naked DNA in therapy: (1) 
they can transport intact DNA across cell membranes and epithelial layers, and (2) the 
polymer of the NPs protect the DNA from nucleases [104]. As macrophages have proven 
difficult to transfect with standard DNA transfection procedures, NPs offer an attractive 
alternative for transfection. Macrophages are thought to most efficiently phagocytose particles 
between 200 and 1000 nm [9]; a fact that led to the work I put in to increasing the size of the 
particles I produced. If the particles are smaller than 200 nm, we expect phagocytosis to not 
be as effective due to the small surface area receptors have to bind, making the signal for 
phagocytosis weak. Unfortunately, I had no success in achieving this goal, despite 
considerable efforts. Even though there are many papers that give instructions on how to 
achieve the optimal size and drug loading, I was unable to overcome the problem of small 
size. For some reason I cannot explain, I was not successful in increasing the overall size of 
the particles. Nevertheless, in parallel I continued with my work to encapsulate pDNA.   
5.2.1 Making plasmid-DNA loaded nanoparticles 
Following my discovery of a paper by Niu et al. [109] where pDNA is encapsulated into 
PLGA-NPs by the nanoprecipitation method, I immediately wanted to try this for myself. Not 
only was the method simple, but the DNA would not be subjected to the detrimental effects of 
sonication. It turned out that the major problem associated with this procedure was dissolving 
pDNA in the solvent, DMSO. In that paper, it was actually not mentioned how DNA is 
dissolved in the DMSO solution, so the procedure that group used remains unclear to us. 
Nevertheless, we sought to solve the problem ourselves, and what we achieved was visible 
dissolution of the pDNA pellet in DMSO through heating and stirring. It is quite possible that 
the pelleted pDNA was not completely dissolved at the moment the solution was used for 
nanoprecipitation, even though it was perceived as so. I imagine that if the pDNA is not 
completely dissolved in the solvent, the molecules will preferentially aggregate and 
encapsulation will not be successful, leading to the escape of pDNA into the non-solvent, 
water.  
As this is the only report of pDNA encapsulation using the nanoprecipitation method, there is 
not much help to be found in the literature. This may be a sign that this method is not 





Nonetheless, my work lays the foundation to find new ways of solving this problem in the 
Griffiths group. In addition, the establishment of the protocols for NP preparation by 
nanoprecipitation and characterization of pDNA integrity will help these future experiments.  
5.3 Rifampicin as a therapeutic agent against  
M.marinum in zebrafish embryos 
Throughout this thesis, the focus on RIF is related to its crucial role in the treatment of TB in 
humans. As M.marinum is also susceptible to RIF [121, 122], one could deduce that the same 
principles in treatment apply. The MIC
6
 (minimum inhibitory concentration) and MEC for 
RIF against this particular strain of M.marinum has been established by Adams et al. 2011 
[119] to be 0.32 µg/ml and by Cosma et al. 2006 [123] to be 320 µg/ml, respectively. These 
are the data my experiments are based on. 
Relevant for my results are the results obtained by Adams et al. 2011 [119]. Some key points 
from that paper include: 
 Continuous treatment of infected embryos with RIF MEC led to a survival rate similar 
to uninfected controls and a 3-day treatment with two times the MEC lead to an 
increased reduction in bacterial load, despite its toxicity (measured by fluorescence 
microscopy). 
 Drug-tolerant bacteria persist in infected zebrafish embryos, and they appear early in 
infection. 
 Development of drug-tolerance depends on macrophage residency and presence of the 
drug. 
 Drug-tolerance is mediated by efflux-pumps and the addition of inhibitors towards 
these pumps leads to a reduction in bacterial load.  
Keeping these issues in mind we chose to use four different antibiotic concentrations to 
evaluate the treatment of M.marinum-infected zebrafish embryos through bath treatment: the 
RIF MEC (320 µg/ml), a sub-optimal concentration (100 µg/ml) and two concentrations 
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above MEC (500 & 640 µg/ml). Since RIF has dose-dependent activity [119, 124], it would 
be interesting to observe if bacterial clearance could be achieved more rapidly at doses higher 
than the MEC.  
Rifampicin bath experiments 
Looking at Figure 16, one can see a clear trend: the higher the concentration of RIF, the 
higher the embryonic survival. This trend can likely be explained by the bactericidal activity 
associated with RIF. The infected control group shows the expected mortality and this is 
supported by the CFU results (Table 1). Also expected was the high mortality observed for 
the 100 µg/ml group, since this is a sub-optimal concentration of RIF. Considering the results 
for the 100 µg/ml group, it appears that this sub-optimal concentration actually increases 
virulence, possibly by the emergence of more tolerant bacilli. These results from the survival 
experiment are, in comparison to the infected control group, not fully supported by CFU 
results; the exception being the results from 9 dpi, where a CFU of 1350 fits well with the fact 
that this group of embryos showed higher mortality than the infected control group. The MEC 
group (320 µg/ml) in this experiment shows poor bactericidal activity, as compared to the 
results presented by Adams et al. 2011, where 320 µg/ml normalizes embryo survival. The 
reasons for this may be a higher amount of tolerant bacteria or increased host susceptibility to 
the infection. The groups treated with 500 and 640 µg/ml were all determined to be 
statistically non-significant relative to the control group, indicating that therapy was 
successful and that, visually, toxicity was not a problem. 
Figure 17 does not show a clear trend, but this could be explained by the clogging of the 
needle during injections. Thus, the bacterial load was expected to be quite variable and lower 
than in experiment nr. 1. In looking at the infected control group in Figure 17, one can clearly 
see that the infection is delayed by 2 days when comparing it to experiment nr. 1 (Figure 16). 
The mortality in the infected control group started at 6 dpi in experiment nr. 1, while it began 
at 8 dpi in nr. 2. One could therefore argue that the results seen for the other groups were also 
delayed by 2 days. Moreover, if the experiment could have progressed longer, we might have 
seen results more similar to the first experiment. The reason for this limited time period of 11 
dpi is that at this time the embryos were 13 days old and were not fed during the course of the 





Although one could question whether this second experiment is reliable at all, the images in 
Figure 18, taken of randomly chosen embryos, show clearly that an infection has been 
initiated and is progressing. From my experience I can say that these images reliably represent 
how a typical infection progresses with the only difference being the initial bacterial load and, 
therefore, how long the embryos survive. The data for the infected control group were the 
only ones determined to be statistically significant by a Log-rank test. Even so, I would argue 
that we can see the beginning of a decreasing survival trend in the 100 and 320 µg/ml groups 
(p = 0.087 and p = 0.103, respectively, when compared to the control group) at the last time 
point and that if it were possible to continue the experiment, the decrease would be greater 
over time. The images in Figure 18 support this hypothesis. A steady increase in bacterial 
load was observed for both the infected control and 100 µg/ml groups. The same increase was 
not observed in the remaining groups due to the bactericidal effect of RIF, but persisting 
tolerant bacteria were observed. The therapeutic effect is especially clear in the images for the 
640 µg/ml group, where at 9 dpi, bacteria were very hard to find or could not be found at all. 
At 7 dpi different bacterial loads were observed, some with a significant amount of bacteria 
and others with hardly any bacteria at all; the latter is consistent with the images from 9 dpi. It 
is important to note that when dealing with a system like this, where multiple individuals are 
used to test the effects of a drug, there will be some inherent biological variation in the 
results. Some may be more susceptible to the infection and others may be quite capable to 
decrease the bacterial load on their own. Due to the clear trend presented in the image analysis 
one can say that the conclusions made here represent the majority.  
In comparison to Adams et al. 2011, the results obtained here were quite different. They 
reported 100 % mortality of uninfected embryos treated with two times the MEC, i.e. 640 
µg/ml, within 6 days of treatment. This finding is not supported by my results as the 
difference between the 640 µg/ml groups and the control groups in both experiments (most 
importantly in the first due to the higher bacterial load) was determined to be non-significant 
by statistical analyses. At the most, approximately 30 % mortality was observed for this group 
over a period of 11 days. I cannot claim that the embryos experience no toxicity at all, but 
based on my results, I can safely claim that this concentration will not kill them.  
As for the MEC groups, different survival was observed in the two experiments; 30 % 
survival for experiment nr. 1 and 60 % for nr. 2. In the former, the survival declines from 70 
to 30 % in two days, making it reasonable to suggest that if it had not been for the 2-day 





the results reported by Adams et al. where by 11 days of treatment, 70 – 80 % of infected 
embryos were still alive. The reason for these different results is hard to interpret, since the 
same strains of M.marinum and zebrafish were used. The differences, therefore, must lie in 
the experimental design. For example, we inject approximately 25 bacilli, determined by 
CFU, while they report infection with 800 bacilli, estimated by a procedure that is not evident 
in their publication. Even so, the infected control groups in both experiments experienced 
mortality around the same time; day 6 – 7, but compared to my results, the decline in survival 
is steeper in the data presented by Adams et al. 2011. Therefore, it could be possible that the 
amount of bacteria injected does not significantly affect the rate of killing in zebrafish 
embryos in the range between 25 – 800 bacilli, or that different methods are used to estimate 
this amount of bacteria, but as this is not mentioned by Adams et al. it is hard to say.     
Obviously these experiments need to be repeated as completely reproducible and interpretable 
results were not obtained, but my data agree with some of the data presented by Adams et al. 
2011 in that tolerance towards RIF plays a significant role in treatment failure. This can be 
stated because M.marinum growth should be inhibited by RIF, as proven in vitro [123], but as 
shown by Adams et al. 2011, this is not the case in vivo. The bacterium has developed a 
system where the effects of antibiotics can be circumvented by up-regulation of efflux pump 
numbers or activity. This transient phenotypic change is called tolerance. Creating a treatment 
strategy where inhibitors towards these pumps are used in combination with antibiotics 
provides an attractive strategy to focus on in future experiments. In addition, with the use of 
RIF loaded NPs, a therapeutic concentration can be achieved inside the macrophage (the site 
of infection), possibly circumventing this problem all together. This is something that needs 
to be further evaluated in the future.    
CFU enumeration 
In addition to the fact that counts below 30 are statistically unreliable when doing CFU [62], I 
suspect that there may be a threshold for detection; thus, when one’s counts are below a 
certain number, the variability in the number of colonies that form is very high. This seems to 
be the case for the 500 and 640 µg/ml groups and is probably one of the main flaws of CFU 
enumeration. The low counts observed in the results presented (Table 1) can also be due to 
errors performed during the process, such as inconsistent pipetting or more likely, failure to 





clumps in culture it is not unreasonable to think that this could be the case because if two or 
more bacteria are clumped when plated, only one colony will arise. And it is important to 
keep in mind that we are counting colony forming units, not all viable bacterial cells. The 
CFU will therefore always be an underestimate of the true number of viable bacteria. 
I conclusion, I would say that this method needs to be further optimized. This is underscored 
by the fact that no CFU results were obtained from experiment nr. 2 and that it takes more 
than 1 bacterium to induce the mortality observed for the 320 µg/ml group in Figure 16.  
5.4 The effect of thioridazine on bacterial load 
As explained earlier, TZ has great potential as a therapeutic agent against mycobacteria; both 
alone and in concert with antibiotics. Since Adams et al. 2011 reported that tolerance towards 
antibiotics is induced by efflux pumps and that efflux pump inhibitors reduced the bacterial 
load even more than with antibiotics alone, the thought of using an efflux pump inhibitor in 
combination with an antibiotic to eradicate a mycobacterial infection has been a compelling 
idea. We therefore sought to try a combination of TZ and RIF in the M.marinum-zebrafish 
model system.  
We found that above a certain concentration the toxicity of this compound was quite severe 
and that relatively low concentrations needed to be used (Figure 19). We chose to use 0.1 
µg/ml, in spite of some toxicity observed at this concentration, with the rationale that this 
compound would eventually be encapsulated and that systemic toxicity might no longer be a 
problem. Keeping in mind that approximately 40 % of the embryos will die due to toxicity, 
we still hoped to observe some therapeutic effect through fluorescence microscopy in the 
period before mortality became too high. Indeed, a therapeutic effect is seen for the group 
treated with 0.1 µg/ml TZ in combination with 320 µg/ml RIF (Figure 21), but whether or not 
it is significantly more than what was observed for the embryos treated with only 320 µg/ml 
RIF, is difficult to conclude. In this experiment, 320 µg/ml RIF had a much greater 
bactericidal effect than observed earlier (Figure 16 and 20). The reason for this is not clear; 
the bacterial load may have been affected due to some clogging of the needle during injection 
or it may be natural variability amongst the embryos. Either way, the effect was great enough 





The same determination was made for the group treated with RIF and 0.01 µg/ml TZ, but I 
believe that this therapeutic effect is due to the RIF not the TZ. This is supported by the fact 
that there was no additional bactericidal effect observed in combination with RIF (Figure 21), 
and 0.01 µg/ml TZ did not have any bactericidal effect on its own (Figure 20 and 21). The 
same lack of bactericidal effect was observed for 0.1 µg/ml TZ as well. Therefore, in contrast 
to what has been reported, TZ did not under these circumstances show any bactericidal 
activity on its own, and it thereby makes it hard to conclude if there was any activity in 
combination with RIF as well.  
These results are preliminary and this experiment needs to be repeated. Here and now it does 
not seem like TZ helps decrease the bacterial load significantly during infection, despite all 
the promising results that have been reported for this compound, but one must keep in mind 
that most experiments have been done in macrophage cell cultures relative to in vivo 
experiments. Therefore, more optimization of the system may be necessary. In addition, one 
can hypothesize that the reason for TZ’s lack of activity could be the absence of efflux pump 
up-regulation all together. Other mechanisms of tolerance are known and have been shown in 
mycobacteria, e.g. rescue of the RNA polymerase from inhibition by RIF [125]. Obviously 
this is speculation as this is a phenomenon we know little about at the moment, and that 








The conclusions that can be drawn from this Master’s thesis are: 
 A procedure for obtaining small and uniformly distributed NPs was established. 
 Protocols for pDNA-encapsulation and pDNA characterization were established. 
 pDNA-encapsulation was not successful and thus, our particles could not yet be 
evaluated for therapeutic purposes. 
 Treatment of M.marinum-infected zebrafish embryos with rifampicin induces 
tolerance towards the drug. 
 The effect of TZ was evaluated by preliminary experiments and shown not to be as 
effective as we had expected. 
 CFU enumeration needs to be further optimized.  
















7 Future perspectives 
Nanoparticle preparation can be a lengthy process and the procedure needs to be continuously 
optimized until the desired properties are obtained. These properties include drug loading 
efficiency, size, surface modifications and etc. In the present work pDNA encapsulation was 
not successful due to reasons discussed earlier, therefore, new strategies need to be explored. 
One possibility, already used by some groups, could be to complex pDNA with polyethylene 
glycol (PEG). These nano-scale complexes have been shown to dissolve in selected organic 
solvents, such as DMSO [108]. Creating these complexes beforehand and dissolving them 
directly in the DMSO could be the answer to encapsulating pDNA with the nanoprecipitation 
method. Otherwise, I fear a different method of encapsulation, such as double emulsion, will 
have to be considered, despite the fact that there will be a risk of damage to the pDNA and 
that it will require a considerable amount of time and work.  
After successful pDNA encapsulation, the NPs should be tested as therapeutic agents in BCG-
infected macrophages and in M.marinum-infected zebrafish embryos. In addition, quantitative 
analyses of pDNA release from the NPs should be performed. The levels of gene expression 
should be evaluated using quantitative PCR and sub-cellular localization should be observed 
due to the GFP construct associated with the antimicrobial peptide. These studies will be 
important in establishing pDNA-NPs as therapeutic agents.      
Preparation of particles with the optimal size was also not successful, but this can be used as 
an advantage. In addition to the work we are doing on TB therapy, we are also going to start 
exploring the possibilities of using NPs in cancer therapy as well. In that case, the protocol I 
established for the fabrication of these small NPs may be ideal for that purpose, since the 
particles need to travel through small capillaries to reach the cancerous sites of the human 
body.   
One of the observations I made concerning RIF therapy was the same as Adams et al. 2011 
[119]; some bacteria develop tolerance and persist during treatment. On the other hand, I did 
not obtain the same results concerning treatment with the MEC, 320 µg/ml, or the degree of 
toxicity observed when using a higher concentration of RIF (640 µg/ml). Due to these 
differences I would advise that more consistent data need to be collected in the form of 
repetition, and that quantitative analyses of RIF concentration inside treated embryos, in the 





In addition to RIF, disappointing results were also obtained for TZ. TZ is reported to have 
considerable bactericidal activity against M.tb on its own and in combination with antibiotics. 
These effects were not observed in the preliminary experiment performed in this thesis’ work, 
but as this was preliminary, the experiment should be repeated. There is some promise for TZ 
in our group since my colleague Raja Kalluru has recently shown that TZ free in solution, in 
conjunction with RIF-NPs is able to significantly improve the killing of BCG in mouse 
primary macrophages relative to cells treated with only RIF-NP. Efforts are now ongoing in 






















 Calculations for 100 µg/ml and 320 µg/ml are for a total volume of 90 ml (approx. 3 
days worth of solution). 
100 µg/ml: in 100 ml embryo water 10 mg RIF would have to be added to make a 100 µg/ml 
solution. 90 ml/100 ml = 0.9, this factor is used to calculate the amount of RIF needed in 90 
ml embryo water: 10 mg RIF x 0.9 = 9 mg RIF 
RIF is dissolved in 1 % DMSO, here 0.9 ml 
0.9 ml RIF-DMSO solution is added to 90 ml – 0.9 ml = 89.1 ml embryo water. 
320 µg/ml: to make 100 ml of a 320 µg/ml solution one needs 32 mg. 
As above, 32 mg RIF x 0.9 = 28.8 mg RIF in 0.9 ml DMSO and subsequently 89.1 ml embryo 
water. 
 The total volume for 500 µg/ml and 640 µg/ml solutions is 180 ml. The solutions are 
double because of the control groups.  
500 µg/ml: for 100 ml of a 500 µg/ml solution one needs 50 mg. 
The factor for calculation is now, 180 ml/100 ml = 1.8.  
50 mg RIF x 1.8 = 90 mg RIF in 1.8 ml DMSO (1 % of total volume)  
1.8 ml RIF-DMSO is added to 180 ml – 1.8 ml = 178.2 ml embryo water.   
640 µg/ml: to make 100 ml of a 640 µg/ml solution one needs 64 mg. 








The following recipes are taken from Cosma et al. 2006 [115]. 
Embryo water: 
1.0 ml Hanks’ stock solution #1 
0.1 ml Hanks’ stock solution #2 
1.0 ml Hanks’ stock solution #4 
95.9 ml H2O 
1.0 ml Hanks’ stock solution #5 
1.0 ml Hanks’ stock solution #6 
Adjust pH to 7.2, filter sterilize and store indefinitely at 4°C.  
Hanks’ stock solutions: 
Stock #1: 8.0 g NaCl 
0.4 g KCl 
100 ml H2O   
Stock #2: 0.358 g Na2HPO4 anhydrous 
0.6 g KH2PO4 
100 ml H2O 
Stock #4: 0.72 g CaCl2 
50 ml H2O 
Stock #5: 1.23 g MgSO4·7H2O 
50 ml H2O 
Stock #6: 0.35 g NaHCO3 
10 ml H2O 






M. marinum freezing medium: 
This recipe is taken from Gao et al. 2005 [63]. 
Add the following components to 140 ml H2O with constant stirring at room temperature and 
continue stirring for 10 min:  
60 ml glycerol 
1 ml 10 (v/v) Tween 80 
Pass through a 0.22-µm filter to sterilize 
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